

Rivaroxaban versus Enoxaparin for Thromboprophylax

New England Journal of Medicine

358, 2765-2775

DOI: [10.1056/nejmoa0800374](https://doi.org/10.1056/nejmoa0800374)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oral Factor Xa Inhibitors for Venous Thromboembolism Prevention in Major Orthopedic Surgery: A Review. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 217-226.	0.5	3
2	DVT: current approaches to diagnosis and treatment. The Prescriber, 2008, 19, 15-22.	0.1	1
3	Rivaroxaban, une nouvelle h��parine par voie orale. Option/Bio, 2008, 19, 5.	0.0	0
5	Prevention of Venous Thromboembolism After Surgery. Clinics in Geriatric Medicine, 2008, 24, 625-639.	1.0	8
6	Rivaroxaban for Thromboprophylaxis. New England Journal of Medicine, 2008, 359, 2174-2176.	13.9	19
11	Warfarin replacements: Mechanisms underlying emerging agents. Canadian Journal of Cardiology, 2008, 24, 56C-60C.	0.8	4
14	Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Current Medical Research and Opinion, 2008, 24, 2757-2765.	0.9	236
15	New Issues in Oral Anticoagulants. Hematology American Society of Hematology Education Program, 2008, 2008, 259-265.	0.9	19
16	Combined Therapies. Neurosurgery, 2008, 63, N12.	0.6	4
18	Prevention and treatment of venous thromboembolism in older people. Reviews in Clinical Gerontology, 2008, 18, 219-228.	0.5	3
19	Development of New Anticoagulants: Present and Future. Seminars in Thrombosis and Hemostasis, 2008, 34, 779-793.	1.5	28
20	New Anticoagulants â€” The Path from Discovery to Clinical Practice. New England Journal of Medicine, 2008, 358, 2827-2829.	13.9	13
21	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€™ DVT Dose-Ranging Study. Blood, 2008, 112, 2242-2247.	0.6	316
22	Clinical Applications of Aspirin. , 0, , 223-365.		0
23	Controversies in the antiphospholipid syndrome: can we ever stop warfarin?. Journal of Autoimmune Diseases, 2008, 5, 6.	1.0	17
24	Seizure Termination by Acidosis Depends on ASIC1a. Neurosurgery, 2008, 63, N10.	0.6	4
25	Health Care Reform Tops Presidential Candidates' Agenda. Neurosurgery, 2008, 63, N13-N14.	0.6	0
26	Shunting for Alzheimer's Disease. Neurosurgery, 2008, 63, N11.	0.6	0

#	ARTICLE	IF	CITATIONS
27	Genome Search Reveals Gene Variants Associated with Low Bone Mineral Density and Fractures in Osteoporosis. <i>Neurosurgery</i> , 2008, 63, N12.	0.6	0
28	Neuromotor Prosthetics. <i>Neurosurgery</i> , 2008, 63, N8-N9.	0.6	2
29	Engineering the Ideal Bypass Graft. <i>Neurosurgery</i> , 2008, 63, N9.	0.6	0
30	Orally Administered Factor Xa Inhibitor, Rivaroxaban. <i>Neurosurgery</i> , 2008, 63, N10-N11.	0.6	3
31	Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1373-1386.	1.0	22
32	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2008, 43, 1024-1029.	0.4	1
33	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2008, 43, 770-774.	0.4	0
34	The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. <i>Vascular Health and Risk Management</i> , 2009, 5, 693.	1.0	18
35	The direct factor Xa inhibitor rivaroxaban. <i>Medical Journal of Australia</i> , 2009, 190, 379-383.	0.8	19
37	Venous thromboembolism: a UK perspective. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overbo 0,2		
38	Nouveaux anticoagulants: premier bilan. <i>Sang Thrombose Vaisseaux</i> , 2009, 21, 389-395.	0.1	1
39	New anticoagulants "towards the development of an "ideal" anticoagulant. <i>Vasa - European Journal of Vascular Medicine</i> , 2009, 38, 13-29.	0.6	25
40	Deep Vein Thrombosis in Orthopedic Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 512-516.	0.7	12
41	New Antithrombotic Drugs: Potential for Use in Oncology. <i>Journal of Clinical Oncology</i> , 2009, 27, 4912-4918.	0.8	27
42	The CMS Ruling on Venous Thromboembolism After Total Knee or Hip Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1063.	3.8	75
43	Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 569-576.	0.6	14
44	New Anticoagulants for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 515-524.	1.5	51
47	Reducing vascular risk "venous thromboembolism and anticoagulation. <i>Clinical Risk</i> , 2009, 15, 90-92.	0.1	0

#	ARTICLE	IF	CITATIONS
48	Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2009, 91-B, 636-644.	3.4	152
49	State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 377-388.	0.7	43
50	Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. <i>New England Journal of Medicine</i> , 2009, 361, 594-604.	13.9	652
51	Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor. <i>Pharmacotherapy</i> , 2009, 29, 167-181.	1.2	44
52	Rivaroxaban "an oral, direct Factor Xa inhibitor" lessons from a broad clinical study programme. <i>European Journal of Haematology</i> , 2009, 82, 339-349.	1.1	52
53	Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 107-110.	1.9	98
54	Prophylactic Modalities: Pharmacologic and Mechanical Compression. <i>Seminars in Arthroplasty</i> , 2009, 20, 235-240.	0.3	0
55	The Future of Thromboembolic Prophylaxis. <i>Seminars in Arthroplasty</i> , 2009, 20, 251-254.	0.3	0
56	Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2009, 19, 529-533.	0.6	0
58	Barriers to the optimal use of anticoagulants after orthopaedic surgery. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2009, 129, 1441-1445.	1.3	12
59	Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 106-116.	1.0	2
60	Treatment of venous thromboembolism: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 270-275.	1.0	15
61	Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. <i>Internal and Emergency Medicine</i> , 2009, 4, 471-477.	1.0	8
62	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. <i>Advances in Therapy</i> , 2009, 26, 1058-1071.	1.3	8
66	The prevention of hospital-acquired venous thromboembolism in the United Kingdom. <i>British Journal of Haematology</i> , 2009, 144, 642-652.	1.2	34
67	Thromboprophylaxis in patients with lower limb immobilisation "review of current status. <i>British Journal of Haematology</i> , 2009, 146, 361-368.	1.2	36
68	Are the new oral anticoagulant agents easy to use? Report from an orthopaedic ward. <i>British Journal of Haematology</i> , 2009, 146, 461-464.	1.2	0
69	New Antithrombotic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 139-146.	2.3	87

#	ARTICLE	IF	CITATIONS
70	Novel oral anticoagulants. <i>International Journal of Clinical Practice</i> , 2009, 63, 630-641.	0.8	29
72	New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell. <i>ANZ Journal of Surgery</i> , 2009, 79, 773-774.	0.3	1
73	The role of angiogenesis in melanoma metastasis. <i>ANZ Journal of Surgery</i> , 2009, 79, 774-776.	0.3	0
74	Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 889-891.	1.9	11
75	Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1313-1320.	1.9	72
76	Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 2149-2151.	1.9	7
77	Atrial fibrillation and coagulation: Who and when?. <i>Blood Reviews</i> , 2009, 23, 241-244.	2.8	6
78	The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2009, 91-B, 776-783.	3.4	157
79	A new era for anticoagulants. <i>European Journal of Internal Medicine</i> , 2009, 20, 562-568.	1.0	48
81	Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?. <i>Archives of Cardiovascular Diseases</i> , 2009, 102, 327-333.	0.7	14
82	Preoperative and postoperative care in gynaecology. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2009, 19, 68-74.	0.1	2
84	Intraspinal Hematoma Following Neuraxial Anesthesia and Low-Molecular-Weight Heparin in Two Patients: Risks and Benefits of Anticoagulation. <i>PM and R</i> , 2009, 1, 389-396.	0.9	2
85	New oral anticoagulants to revolutionise venous thromboembolism (VTE) management. <i>Journal of Orthopaedic Nursing</i> , 2009, 13, 165-171.	0.2	4
86	Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. <i>Clinical Pharmacokinetics</i> , 2009, 48, 1-22.	1.6	466
87	Rivaroxaban. <i>Drugs</i> , 2009, 69, 1829-1851.	4.9	38
88	International Recommendations for the Prevention and Treatment of Venous Thromboembolism Associated with Cancer. <i>Clinical Drug Investigation</i> , 2009, 29, 625-633.	1.1	6
89	Chapter 9 Recent Advances in Coagulation Serine Protease Inhibitors. <i>Annual Reports in Medicinal Chemistry</i> , 2009, 44, 189-208.	0.5	4
91	Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. <i>Expert Review of Hematology</i> , 2009, 2, 357-360.	1.0	1

#	ARTICLE	IF	CITATIONS
92	Recent developments in the use of oral anticoagulants. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1769-1781.	0.9	8
93	Rivaroxaban, the first oral, direct factor Xa inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2945-2946.	0.9	3
94	Novel anticoagulants and the future of anticoagulation. <i>Thrombosis Research</i> , 2009, 123, S50-S55.	0.8	17
95	Rivaroxaban for thromboprophylaxis in major orthopedic surgery. <i>Community Oncology</i> , 2009, 6, 295-296.	0.2	0
96	Promising alternative to current drugs for thromboprophylaxis, but studies in cancer patients are lacking. <i>Community Oncology</i> , 2009, 6, 296-298.	0.2	0
98	Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. <i>Lancet, The</i> , 2009, 373, 1673-1680.	6.3	898
99	Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet, The</i> , 2009, 374, 29-38.	6.3	611
100	Rivaroxaban in acute coronary syndromes: too soon to know?. <i>Lancet, The</i> , 2009, 374, 3-4.	6.3	1
102	Overview of Current Venous Thromboembolism Protocols in Hip Reconstruction. <i>Orthopedic Clinics of North America</i> , 2009, 40, 427-436.	0.5	2
103	Interpretation of Benefit-Risk of Enoxaparin as Comparator in the RECORD Program: Rivaroxaban Oral Tablets (10 milligrams) for Use in Prophylaxis in Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Hip or Knee Replacement Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 389-394.	0.7	28
104	Rivaroxaban in Orthopedic Surgery – A Change of Paradigm?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 613-620.	0.7	1
105	Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1083-1088.	0.9	11
106	A logical approach to surgical thromboprophylaxis. <i>Current Opinion in Hematology</i> , 2009, 16, 397-401.	1.2	1
107	New anticoagulants and regional anesthesia. <i>Current Opinion in Anaesthesiology</i> , 2009, 22, 661-666.	0.9	37
108	Intermittent pneumatic compression and pharmacologic thrombosis prophylaxis. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 439-442.	1.2	4
109	Rivaroxaban. <i>Cardiology in Review</i> , 2009, 17, 192-197.	0.6	17
111	Low-molecular-weight heparin for thromboprophylaxis. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 443-454.	1.2	6
112	Use of Emerging Oral Anticoagulants in Clinical Practice. <i>Annals of Surgery</i> , 2009, 250, 219-228.	2.1	30

#	ARTICLE	IF	CITATIONS
113	Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 616-623.	0.6	23
114	American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. <i>Chest</i> , 2009, 135, 513-520.	0.4	200
115	Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. <i>Thrombosis and Haemostasis</i> , 2009, 102, 892-899.	1.8	65
116	Anticoagulation with Âdabigatran orÂrivaroxaban. <i>Drug and Therapeutics Bulletin</i> , 2009, 47, 116-120.	0.3	2
117	New Anticoagulants: Focus on Venous Thromboembolism. <i>Current Vascular Pharmacology</i> , 2009, 7, 309-329.	0.8	26
118	Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. <i>Current Opinion in Hematology</i> , 2009, 16, 347-356.	1.2	24
119	Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 187-189.	0.2	1
120	The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 722-725.	0.9	4
121	New Anticoagulants for the Prevention of Thromboembolism. <i>Current Pharmaceutical Design</i> , 2010, 16, 3472-3474.	0.9	3
122	Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism. <i>Current Vascular Pharmacology</i> , 2010, 8, 5-11.	0.8	4
123	Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management. <i>Current Pharmaceutical Design</i> , 2010, 16, 3436-3441.	0.9	83
124	Implementing a venous thromboembolism (VTE) prevention strategy. <i>Clinical Governance</i> , 2010, 15, 19-28.	0.4	3
125	Treatment options in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2010, 17, 424-431.	1.2	11
126	Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2010, 25, 312-320.	0.8	32
127	The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?. <i>Thrombosis and Haemostasis</i> , 2010, 103, 34-39.	1.8	43
129	Gadolinium-Enhanced Magnetic Resonance Angiography for Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2010, 152, 434.	2.0	330
130	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. <i>Thrombosis and Haemostasis</i> , 2010, 104, 642-649.	1.8	144
131	Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2010, 104, 919-930.	1.8	30

#	ARTICLE	IF	CITATIONS
132	The new oral anticoagulants. Netherlands Heart Journal, 2010, 18, 314-318.	0.3	15
134	Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2010, 66, 1099-1108.	0.8	60
135	Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Archives of Orthopaedic and Trauma Surgery, 2010, 130, 583-589.	1.3	17
136	Readmissions after fast-track hip and knee arthroplasty. Archives of Orthopaedic and Trauma Surgery, 2010, 130, 1185-1191.	1.3	138
137	Nuovi farmaci antitrombotici in chirurgia ortopedica: dagli studi clinici all'uso nella pratica quotidiana. Archivio Di Ortopedia E Reumatologia, 2010, 121, 32-35.	0.0	0
138	New and Emerging Anticoagulant Therapies for Venous Thromboembolism. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 142-155.	0.4	5
139	Nonadherence in Outpatient Thrombosis Prophylaxis with Low Molecular Weight Heparins after Major Orthopaedic Surgery. Clinical Orthopaedics and Related Research, 2010, 468, 2437-2453.	0.7	41
141	Update in Perioperative Medicine. Journal of General Internal Medicine, 2010, 25, 1346-1351.	1.3	1
142	Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell'anca e del ginocchio e nelle fratture del collo femorale. LO SCALPELLO-OTODI Educational, 2010, 24, 206-211.	0.1	3
143	Newer anticoagulants in 2009. Journal of Thrombosis and Thrombolysis, 2010, 29, 92-104.	1.0	41
144	New oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Thrombolysis, 2010, 29, 182-191.	1.0	38
145	Deep Vein Thrombosis Propylaxis: Better Living Through Chemistry-Affirms. Seminars in Arthroplasty, 2010, 21, 80-84.	0.3	0
146	The potential benefits of low-molecular-weight heparins in cancer patients. Journal of Hematology and Oncology, 2010, 3, 3.	6.9	35
147	Regional anaesthesia and anticoagulation. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2010, 24, 121-131.	1.7	22
148	Meeting the Unmet Needs in Anticoagulant Therapy. European Journal of Haematology, 2010, 85, 1-28.	1.1	87
150	Laboratory monitoring of new anticoagulants. American Journal of Hematology, 2010, 85, 185-187.	2.0	29
151	Clinically significant thromboembolic disease in orthopedic oncology: An analysis of 986 patients treated with low-molecular-weight heparin. Journal of Surgical Oncology, 2010, 102, 375-379.	0.8	12
152	Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX2). Journal of Thrombosis and Haemostasis, 2010, 8, 714-721.	1.9	59

#	ARTICLE	IF	CITATIONS
153	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1966-1975.	1.9	68
154	Drug and dietary interactions of the new and emerging oral anticoagulants. <i>International Journal of Clinical Practice</i> , 2010, 64, 956-967.	0.8	136
155	Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery. <i>Anaesthesia</i> , 2010, 65, 552-555.	1.8	1
156	Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 703-712.	1.1	362
157	New aspects on treatment modalities for thromboembolic episodes. <i>Journal of Internal Medicine</i> , 2010, 268, 109-119.	2.7	3
158	The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. <i>British Journal of Haematology</i> , 2010, 151, 469-476.	1.2	28
159	New anticoagulants for the prevention of venous thromboembolism. <i>Drug Design, Development and Therapy</i> , 2010, 4, 49.	2.0	23
160	Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. <i>Thrombosis and Haemostasis</i> , 2010, 104, 760-770.	1.8	51
161	Simplifying Thromboprophylaxis Could Improve Outcomes in Orthopaedic Surgery. <i>Thrombosis</i> , 2010, 2010, 1-5.	1.4	2
162	New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty. <i>Thrombosis</i> , 2010, 2010, 1-9.	1.4	1
163	Rivaroxaban vs Dabigatran for Thromboprophylaxis After Joint-replacement Surgery: Exploratory Indirect Comparison Based on Meta-Analysis of Pivotal Clinical Trials. <i>Croatian Medical Journal</i> , 2010, 51, 113-123.	0.2	38
164	Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. <i>Thrombosis and Haemostasis</i> , 2010, 104, 504-513.	1.8	5
165	Thromboprophylaxis in Orthopaedic Surgery: A Clinical Review. <i>Journal of Perioperative Practice</i> , 2010, 20, 358-362.	0.3	7
166	Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban " an oral, direct factor Xa inhibitor " in elderly Chinese subjects. <i>Thrombosis and Haemostasis</i> , 2010, 103, 234-241.	1.8	62
167	Facts and artefacts of coagulation assays for factor Xa inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 103, 686-688.	1.8	17
168	Is there adequate provision of venous thrombo-embolism prophylaxis following hip arthroplasty? An audit and international survey. <i>Annals of the Royal College of Surgeons of England</i> , 2010, 92, 668-672.	0.3	10
169	Update on Rivaroxaban. <i>Clinical Medicine Blood Disorders</i> , 2010, 3, CMBD.S5101.	0.2	1
170	Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations. <i>Journal of Blood Medicine</i> , 2010, 1, 123.	0.7	3

#	ARTICLE	IF	CITATIONS
171	Venous thromboembolism following prolonged cast immobilisation for injury to the tendo Achillis. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2010, 92-B, 646-650.	3.4	74
172	Rivaroxaban: A New Oral Factor Xa Inhibitor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 376-381.	1.1	233
173	Emerging anticoagulants for venous thromboembolism prevention. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S17-S25.	0.5	6
174	New oral anticoagulant drugs in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2010, 104, 49-60.	1.8	218
175	Review: Will Warfarin Ever Be Replaced?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 210-219.	1.0	11
176	Anticoagulation in the Elderly. <i>Pharmaceuticals</i> , 2010, 3, 3543-3569.	1.7	23
178	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	1.6	262
180	Treatment options for deep vein thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1069-1075.	0.9	1
181	Emerging drugs for venous thromboembolism. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 107-117.	1.0	2
182	Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 652-660.	0.9	76
183	Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. <i>New England Journal of Medicine</i> , 2010, 363, 2487-2498.	13.9	691
184	Clinical and management challenges in preventing venous thromboembolism in health systems: A case-based panel discussion. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S26-S30.	0.5	1
185	Risk Factors for Venous Thromboembolism in Patients Undergoing Total Hip Replacement and Receiving Routine Thromboprophylaxis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2010, 92, 2156-2164.	1.4	108
186	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. <i>Side Effects of Drugs Annual</i> , 2010, , 617-663.	0.6	0
187	Low risk of thromboembolic complications after fast-track hip and knee arthroplasty. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2010, 81, 599-605.	1.2	133
188	Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants. <i>Current Pharmaceutical Design</i> , 2010, 16, 3478-3482.	0.9	9
189	Warfarin Versus New Agents: Interpreting the Data. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 221-228.	0.9	38
190	Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <i>European Journal of Anaesthesiology</i> , 2010, 27, 999-1015.	0.7	447

#	ARTICLE	IF	CITATIONS
193	Novel oral anticoagulants to prevent stroke in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2010, 7, 149-154.	6.1	14
194	Latest drug developments in the field of cardiovascular disease. <i>International Journal of Angiology</i> , 2010, 19, e100-e105.	0.2	15
196	Venous Thromboembolism: A Clinical Review. <i>Postgraduate Medicine</i> , 2010, 122, 54-65.	0.9	35
197	Rivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1061-1071.	0.9	10
198	Tromboembolismo venoso postoperatorio. <i>Colombian Journal of Anesthesiology</i> , 2010, 38, 499-507.	0.5	3
199	Oral Xa Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 727-737.	0.9	6
202	Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 986-1000.	1.0	6
203	New oral anticoagulants in development. <i>Thrombosis and Haemostasis</i> , 2010, 103, 62-70.	1.8	101
204	Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2067-2076.	1.2	67
205	Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. <i>Drugs</i> , 2010, 70, 1.	4.9	33
206	New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors. <i>Clinics in Chest Medicine</i> , 2010, 31, 707-718.	0.8	8
208	Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. <i>Thrombosis Research</i> , 2010, 126, 175-182.	0.8	140
210	Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. <i>American Heart Journal</i> , 2010, 159, 340-347.e1.	1.2	395
211	REVIEW: New Antithrombotics for Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2010, 28, 278-286.	1.1	19
212	Potential of new anticoagulants in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S30-S35.	0.8	14
213	Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. <i>Lancet, The</i> , 2010, 375, 807-815.	6.3	716
214	New antithrombotic agents—insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010, 7, 498-509.	6.1	45
215	Tratamiento con anticoagulantes orales: inicio, ajuste y precauciones en su utilizaci3n. <i>Avances En DiabetologÃa</i> , 2010, 26, 17-20.	0.1	3

#	ARTICLE	IF	CITATIONS
216	Factor Xa Inhibitors: Next-Generation Antithrombotic Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6243-6274.	2.9	116
217	Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?. <i>Lupus</i> , 2010, 19, 486-491.	0.8	45
220	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. <i>Thrombosis and Haemostasis</i> , 2010, 103, 572-585.	1.8	119
221	Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor) Tj ETQq1 1 0.784314 rgBT /Over	1.0	18
222	Treatment of thromboembolism in cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2049-2058.	0.9	8
223	Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement. <i>Pharmacoeconomics</i> , 2010, 28, 781-782.	1.7	3
224	The new oral anticoagulants. <i>Blood</i> , 2010, 115, 15-20.	0.6	268
225	Old and new anticoagulant drugs: A minireview. <i>Annals of Medicine</i> , 2011, 43, 116-123.	1.5	48
226	Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. <i>Phlebology</i> , 2011, 26, 3-7.	0.6	4
227	Dutch guideline on total hip prosthesis. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2011, 82, 567-576.	1.2	30
228	Response to "Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban". <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1122-1123.	1.0	0
230	Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. <i>Evidence-Based Medicine</i> , 2011, 16, 139-140.	0.6	1
232	Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient. <i>Advances in Surgery</i> , 2011, 45, 361-390.	0.6	2
233	Faut-il traiter toutes les thromboses post-opÃ©ratoires ?. <i>Praticien En Anesthesie Reanimation</i> , 2011, 15, H5-H9.	0.0	0
234	New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 45-57.	1.8	20
235	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
236	Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH). <i>Drug Safety</i> , 2011, 34, 243-252.	1.4	98
237	A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. <i>Drug Safety</i> , 2011, 34, 449-463.	1.4	20

#	ARTICLE	IF	CITATIONS
238	Rivaroxaban. <i>Clinical Pharmacokinetics</i> , 2011, 50, 675-686.	1.6	301
239	Edoxaban. <i>Drugs</i> , 2011, 71, 1503-1526.	4.9	98
240	New anticoagulants: Moving on from scientific results to clinical implementation. <i>Annals of Medicine</i> , 2011, 43, 606-616.	1.5	9
241	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2333-2335.	13.9	44
242	Enoxaparin: a pharmacologic and clinical review. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1157-1170.	0.9	34
243	Emerging anticoagulants. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 31-44.	1.0	8
245	Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. <i>American Heart Journal</i> , 2011, 161, 815-821.e6.	1.2	88
246	Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Reviews</i> , 2011, 25, 215-221.	2.8	20
247	The incidence of venous thromboembolism in patients undergoing surgery for acute Achilles tendon ruptures. <i>Foot and Ankle Surgery</i> , 2011, 17, 263-265.	0.8	30
248	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	5.0	177
249	Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 218-226.	0.3	30
251	The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. <i>Thrombosis Research</i> , 2011, 127, 497-504.	0.8	117
252	Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis?. <i>Thrombosis Research</i> , 2011, 127, 202-209.	0.8	0
253	Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. <i>Thrombosis Research</i> , 2011, 127, 457-465.	0.8	157
254	A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. <i>Thrombosis Research</i> , 2011, 127, 525-534.	0.8	29
255	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011, 127, S5-S12.	0.8	64
256	Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 601-615.	0.7	26
257	The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. <i>Cardiovascular Therapeutics</i> , 2011, 29, e12-e22.	1.1	10

#	ARTICLE	IF	CITATIONS
258	Alternatives to Warfarin-The Next Generation of Anticoagulants. Cardiovascular Therapeutics, 2011, 29, e80-e88.	1.1	9
259	Management of Bleeding Complications in the Anticoagulated Patient. Seminars in Hematology, 2011, 48, 285-294.	1.8	9
261	Thrombosis in cancer. , 2011, , 274-282.		1
262	Old and new anticoagulants. Hamostaseologie, 2011, 31, 21-27.	0.9	36
263	Novos anticoagulantes em cuidados intensivos. Revista Brasileira De Terapia Intensiva, 2011, 23, 68-77.	0.1	4
264	Venous thromboembolism and bleeding after total knee and hip arthroplasty. Thrombosis and Haemostasis, 2011, 105, 610-615.	1.8	42
265	Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vascular Health and Risk Management, 2011, 7, 461.	1.0	22
266	The Timing of Drug Administration for Thromboprophylaxis Following Orthopaedic Surgery: Evidence and Controversies Related to Treatment Initiation and Duration. Current Vascular Pharmacology, 2011, 9, 11-18.	0.8	4
267	Pharmacologie et Th�rapeutique Vasculaire. , 2011, , 687-843.		0
268	New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Thrombosis and Haemostasis, 2011, 105, 571-573.	1.8	1
269	Profilaxis de enfermedad tromboemb�lica en pacientes hospitalizados con patolog�a m�dica, estrechando la brecha entre las gu�as y la pr�ctica cl�nica. Revista Medica De Chile, 2011, 139, 1210-1227.	0.1	3
270	Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation. PLoS ONE, 2011, 6, e17626.	1.1	32
271	Drugs affecting coagulation and platelet function. , 2013, , 912-947.		0
273	Venous and arterial thrombosis â€“ pathogenesis and the rationale for anticoagulation. Thrombosis and Haemostasis, 2011, 105, 586-596.	1.8	86
274	Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome?. Current Opinion in Anaesthesiology, 2011, 24, 166-170.	0.9	12
275	VTE prophylaxis after total joint arthroplasty. Current Orthopaedic Practice, 2011, 22, 193-197.	0.1	1
276	Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban. American Journal of Therapeutics, 2011, 18, 332-338.	0.5	16
277	An update on the Management and Treatment of Deep Vein Thrombosis. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2011, 9, 207-217.	0.4	3

#	ARTICLE	IF	CITATIONS
278	Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?. <i>Current Vascular Pharmacology</i> , 2011, 9, 350-357.	0.8	3
279	Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 720-726.	0.5	14
280	Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 495-505.	1.9	7
281	Design, findings and implications of the RECORD study program. <i>Clinical Investigation</i> , 2011, 1, 423-428.	0.0	0
282	Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders. <i>Clinical Investigation</i> , 2011, 1, 725-737.	0.0	0
283	Pharmacotherapy of deep-venous thrombosis: current status and future perspective. <i>Clinical Investigation</i> , 2011, 1, 1039-1047.	0.0	0
284	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2011, 105, 444-453.	1.8	250
287	Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 111-124.	0.7	50
288	Inhibitors of propagation of coagulation: factors V and X. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 563-580.	1.1	15
289	New anticoagulants: how to deal with treatment failure and bleeding complications. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 593-603.	1.1	49
290	Inhibitors of coagulation. <i>Haemophilia</i> , 2011, 17, 90-94.	1.0	6
291	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 441-449.	1.9	31
292	S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1375-1382.	1.9	4
293	CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1870-1873.	1.9	16
294	Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1868-1870.	1.9	16
295	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 61-75.	21.5	247
296	The discovery and development of rivaroxaban. <i>Annals of the New York Academy of Sciences</i> , 2011, 1222, 64-75.	1.8	27
297	Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 12-19.	1.9	81

#	ARTICLE	IF	CITATIONS
298	How to prevent, treat, and overcome current clinical challenges of VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 265-274.	1.9	20
299	Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. , 2011, 129, 185-194.		29
300	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, 130, 46-58.		90
301	LÃnea estratÃ©gica 2: Medicina basada en la evidencia. <i>Farmacia Hospitalaria</i> , 2011, 35, 21-27.	0.6	0
302	New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome. <i>Pharmacotherapy</i> , 2011, 31, 975-1016.	1.2	32
303	Novel Oral Anticoagulants and Their Role in Clinical Practice. <i>Pharmacotherapy</i> , 2011, 31, 1175-1191.	1.2	37
304	Management of refractory anti-phospholipid syndrome. <i>Autoimmunity Reviews</i> , 2011, 10, 669-673.	2.5	52
306	Physiciansâ€™ perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 188-195.	1.0	20
307	Prophylaxis for venous thromboembolism: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 122-132.	1.0	6
308	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 407-416.	1.0	105
309	New oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 310-320.	1.0	52
310	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14â€“16, 2010, SÃ£o Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 242-266.	1.0	2
311	Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 417-425.	1.0	31
312	Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. <i>Journal of Orthopaedics and Traumatology</i> , 2011, 12, 69-76.	1.0	21
313	New anticoagulants: pharmacology and clinical studies. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 54-57.	0.5	5
314	Monitoring of direct anticoagulants. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 58-62.	0.5	11
315	Heparin-Induced Thrombocytopenia and Cerebral Venous Sinus Thrombosis: Case Report and Literature Review. <i>Neurocritical Care</i> , 2011, 15, 161-165.	1.2	21
316	The proof for new oral anticoagulants: clinical trial evidence. <i>European Orthopaedics and Traumatology</i> , 2011, 2, 7-14.	0.1	3

#	ARTICLE	IF	CITATIONS
317	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 129-139.	0.6	78
318	Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines. <i>Irish Journal of Medical Science</i> , 2011, 180, 627-632.	0.8	7
319	Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. <i>Thrombosis Journal</i> , 2011, 9, 17.	0.9	20
320	Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. <i>Medicinal Research Reviews</i> , 2011, 31, 202-283.	5.0	28
321	Practical aspects of the oral new anticoagulants. <i>American Journal of Hematology</i> , 2011, 86, 586-590.	2.0	25
322	Venous thromboembolism in the patient with cancer. <i>Cancer</i> , 2011, 117, 1334-1349.	2.0	158
323	Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. <i>Journal of Medical Economics</i> , 2011, 14, 824-834.	1.0	15
324	Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 299-306.	0.7	9
326	Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 567-577.	0.9	10
327	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.4	13
328	Preventing Postsurgical Venous Thromboembolism: Pharmacological Approaches. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 252-266.	1.5	38
329	Prevention and management of TURP-related hemorrhage. <i>Nature Reviews Urology</i> , 2011, 8, 504-514.	1.9	26
330	Rivaroxaban in the contemporary treatment of acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 849-857.	1.9	4
331	Thromboprophylaxis and Regional Anesthesia in the Ambulatory Setting. <i>International Anesthesiology Clinics</i> , 2011, 49, 166-173.	0.3	0
332	Newer Oral Anticoagulants: A Promising Future. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 235-235.	0.7	1
333	Reversal of New Oral Anticoagulants. <i>Circulation</i> , 2011, 124, 1508-1510.	1.6	31
334	Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). <i>Thrombosis and Haemostasis</i> , 2011, 105, 721-729.	1.8	374
335	An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. <i>Journal of Medical Economics</i> , 2011, 14, 238-244.	1.0	11

#	ARTICLE	IF	CITATIONS
336	Venous thromboembolism: risks and prevention. Continuing Education in Anaesthesia, Critical Care & Pain, 2011, 11, 18-23.	0.6	33
337	The new oral anticoagulants. Clinical Medicine, 2011, 11, 467-469.	0.8	4
338	Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban. Journal of Bone and Joint Surgery: British Volume, 2011, 93-B, 91-95.	3.4	93
339	The Role of Apixaban for Venous and Arterial Thromboembolic Disease. Annals of Pharmacotherapy, 2011, 45, 1262-1283.	0.9	16
340	Efficacy and safety of novel anticoagulants compared with established agents. Therapeutic Advances in Hematology, 2011, 2, 175-195.	1.1	13
341	Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opinion on Drug Safety, 2011, 10, 687-696.	1.0	3
342	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiology, 2011, 7, 459-470.	0.5	16
343	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
344	A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovascular Research, 2011, 92, 159-168.	1.8	32
345	Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Canadian Journal of Surgery, 2011, 54, 344-351.	0.5	54
346	A study of thromboprophylactic practices of Scottish orthopaedic surgeons in patients undergoing total hip replacements. Should practice change with new guidelines?. Scottish Medical Journal, 2011, 56, 191-194.	0.7	1
347	Emerging antithrombotic drugs: A review. Annals of Tropical Medicine and Public Health, 2011, 4, 138.	0.1	0
348	Direct Thrombin Inhibitor (Dti) vs. Aspirin in Primary Total Hip and Knee Replacement Using Wound Ooze as the Primary Outcome Measure. A Prospective Cohort Study. HIP International, 2012, 22, 22-27.	0.9	25
349	Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ, The, 2012, 344, e3675-e3675.	3.0	204
350	ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients. American Journal of Health-System Pharmacy, 2012, 69, 2174-2190.	0.5	12
351	Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects. Journal of International Medical Research, 2012, 40, 1688-1707.	0.4	44
352	Conflict of Interest in the Assessment of Thromboprophylaxis After Total Joint Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2012, 94, 27-33.	1.4	20
353	Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement. Annals of Internal Medicine, 2012, 156, 710.	2.0	80

#	ARTICLE	IF	CITATIONS
354	Management of coagulation. <i>Current Opinion in Anaesthesiology</i> , 2012, 25, 86-95.	0.9	4
355	Newer Anticoagulants in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 209-221.	0.6	24
356	Oral Factor Xa and Direct Thrombin Inhibitors. <i>Journal of Burn Care and Research</i> , 2012, 33, 453-461.	0.2	3
358	Anticoagulation Review. <i>Home Health Care Management and Practice</i> , 2012, 24, 88-96.	0.4	0
359	Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. <i>Journal of Medical Economics</i> , 2012, 15, 817-828.	1.0	17
360	Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 729-734.	3.4	39
361	Thromboprophylaxis in Surgical and Medical Patients. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 163-175.	0.8	22
362	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1027-1034.	1.8	25
363	The Novel Oral Anticoagulants: An Update for the Interventional Radiologist. <i>American Journal of Roentgenology</i> , 2012, 199, W376-W379.	1.0	7
364	Emerging Anticoagulants. <i>Current Medicinal Chemistry</i> , 2012, 19, 3388-3416.	1.2	13
365	Medical Management of Venous Thromboembolism: What the Interventional Radiologist Needs to Know. <i>Seminars in Interventional Radiology</i> , 2012, 29, 003-009.	0.3	2
367	New Options for Anticoagulation Following Total Hip Arthroplasty and Total Knee Arthroplasty: New Oral Agents on the Horizon. <i>Hospital Practice (1995)</i> , 2012, 40, 19-26.	0.5	0
368	Preventing Venous Thromboembolic Events After Total Hip Arthroplasty: New Developments in Clinical Practice. <i>Hospital Practice (1995)</i> , 2012, 40, 79-87.	0.5	6
369	Periprocedural Anticoagulant Management. <i>Hospital Practice (1995)</i> , 2012, 40, 40-49.	0.5	2
370	The New Oral Anticoagulants: A Challenge for Hospital Formularies. <i>Hospital Practice (1995)</i> , 2012, 40, 126-128.	0.5	1
371	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 309-323.	1.1	13
372	Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery. <i>Postgraduate Medicine</i> , 2012, 124, 206-214.	0.9	1
373	Primary prevention of venous thromboembolism. <i>Phlebology</i> , 2012, 27, 23-32.	0.6	20

#	ARTICLE	IF	CITATIONS
374	Novel drugs for oral anticoagulation pharmacotherapy. Expert Review of Cardiovascular Therapy, 2012, 10, 473-488.	0.6	6
375	The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 611-627.	0.7	27
376	Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert Review of Cardiovascular Therapy, 2012, 10, 965-972.	0.6	12
377	PHARMACOLOGY CLINICAL. British Journal of Anaesthesia, 2012, 108, ii368-ii386.	1.5	1
378	Wound Complications Following Rivaroxaban Administration. Journal of Bone and Joint Surgery - Series A, 2012, 94, 1554-1558.	1.4	79
379	Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management. ISRN Vascular Medicine, 2012, 2012, 1-22.	0.7	10
380	New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants. Scientifica, 2012, 2012, 1-12.	0.6	0
381	Current Status of New Anticoagulants in the Management of Venous Thromboembolism. Advances in Hematology, 2012, 2012, 1-7.	0.6	18
382	Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis. Orthopaedic Nursing, 2012, 31, 265-278.	0.2	4
383	Pathways for venous thromboembolic prophylaxis in medical and surgical patients. Phlebology, 2012, 27, 33-42.	0.6	26
384	Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants. Current Clinical Pharmacology, 2012, 7, 175-194.	0.2	4
385	Newer Oral Anticoagulant Agents: A New Era in Medicine. Current Cardiology Reviews, 2012, 8, 158-165.	0.6	14
386	Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open, 2012, 2, e001592.	0.8	69
387	Thromboprophylaxis after total hip arthroplasty. Current Orthopaedic Practice, 2012, 23, 377-381.	0.1	0
388	New anticoagulants. Journal of Trauma and Acute Care Surgery, 2012, 73, 983-992.	1.1	28
389	How Safe Is Thromboprophylaxis in Abdominoplasty?. Plastic and Reconstructive Surgery, 2012, 130, 851e-857e.	0.7	52
390	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgia ortopédica de grande porte: revisão do sistema de ensaios clínicos randomizados. Jornal Vascular Brasileiro, 2012, 11, 88-89.	0.1	0
391	Nuevos anticoagulantes: ¿cuántos de nuestros pacientes anticoagulados pueden tomarlos?. Revista Clínica De Medicina De Familia, 2012, 5, 151-157.	0.1	0

#	ARTICLE	IF	CITATIONS
392	Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2012, 108, 903-912.	1.8	19
393	A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. <i>Thrombosis and Haemostasis</i> , 2012, 107, 201-214.	1.8	11
394	Prevention of VTE in Orthopedic Surgery Patients. <i>Chest</i> , 2012, 141, e278S-e325S.	0.4	1,723
395	Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery. <i>Nurse Practitioner</i> , 2012, 37, 6-8.	0.2	1
396	Drugs Used in Vascular Interventional Radiology. <i>Medical Radiology</i> , 2012, , 25-32.	0.0	0
397	Breakthroughs in Anticoagulation: Advent of the Oral Direct Factor Xa Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2012, 26, 740-745.	0.6	11
398	Forty Years in Academic Cardiology. <i>Cardiology in Review</i> , 2012, 20, 265-267.	0.6	0
399	Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2053-2060.	1.9	23
400	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1035-1043.	1.8	25
401	Management consensus guidance for the use of rivaroxaban “an oral, direct factor Xa inhibitor. <i>Thrombosis and Haemostasis</i> , 2012, 108, 876-886.	1.8	155
402	New oral anticoagulants and venous thromboembolic disease. <i>Sang Thrombose Vaisseaux</i> , 2012, 24, 133-142.	0.1	0
403	The promise of novel direct oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 351-360.	0.7	22
404	Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 257-264.	3.4	88
405	Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, Simple Transitions (SST) study. <i>Thrombosis Research</i> , 2012, 130, 709-715.	0.8	9
406	Vitamin K antagonists. <i>Hamostaseologie</i> , 2012, 32, 249-257.	0.9	8
407	A New Generation of Oral Direct Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 569-574.	1.1	31
409	The Future of Anticoagulant Therapy. <i>Cardiovascular Therapeutics</i> , 2012, 30, 255-256.	1.1	1
410	Performance of New Anticoagulants for Thromboprophylaxis in Patients Undergoing Hip and Knee Replacement Surgery. <i>Pharmacotherapy</i> , 2012, 32, 1036-1048.	1.2	4

#	ARTICLE	IF	CITATIONS
411	Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM [®] . <i>Der Anaesthetist</i> , 2012, 61, 948-953.	0.5	57
412	Thromboprophylaxis in major knee and hip replacement surgery: a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 518-525.	1.0	7
413	Avances en el tratamiento antitrombótico. Nuevos anticoagulantes orales para reemplazar a acenocumarol (Sintrom [®]). <i>Medicine</i> , 2012, 11, 1421-1427.	0.0	1
414	The effects of rivaroxaban on the complications of surgery after total hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 1573-1578.	3.4	43
415	Novel oral anticoagulants - key messages for the angiologist. <i>Vasa - European Journal of Vascular Medicine</i> , 2012, 41, 177-191.	0.6	11
417	Revue d'utilisation de deux anticoagulants oraux dans un CHU français: dabigatran etexilate et rivaroxaban. <i>Pharmacien Hospitalier Et Clinicien</i> , 2012, 47, 132-138.	0.3	0
423	Apixaban: A novel oral inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1113-1126.	0.5	30
424	Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1151-1160.	1.8	22
425	Rivaroxaban. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 57-72.	1.0	19
426	Current anticoagulant safety. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 401-413.	1.0	5
427	Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective. <i>Pharmacoeconomics</i> , 2012, 30, 87-101.	1.7	38
428	Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests. <i>Thrombosis Research</i> , 2012, 129, 492-498.	0.8	133
429	Use of anticoagulants in elderly patients. <i>Thrombosis Research</i> , 2012, 129, 107-115.	0.8	57
430	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. <i>Thrombosis Research</i> , 2012, 129, 9-16.	0.8	8
431	Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. <i>Thrombosis Research</i> , 2012, 130, 147-151.	0.8	46
432	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. <i>Thrombosis Research</i> , 2012, 129, 392-400.	0.8	56
433	Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. <i>Thrombosis Research</i> , 2012, 130, 183-191.	0.8	79
434	Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. <i>Future Cardiology</i> , 2012, 8, 533-541.	0.5	6

#	ARTICLE	IF	CITATIONS
435	Oral Direct Factor Xa Inhibitors. <i>Circulation Research</i> , 2012, 111, 1069-1078.	2.0	92
436	Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 266-276.	1.0	20
437	Novel Anticoagulants for Non-valvular Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2012, 21, 463-467.	0.2	7
438	Comparative Effectiveness of Low-Molecular-Weight Heparins versus Other Anticoagulants in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Pharmacotherapy</i> , 2012, 32, 799-808.	1.2	33
439	A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. <i>BMC Health Services Research</i> , 2012, 12, 192.	0.9	20
440	The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 645-661.	2.4	16
441	Oral factor Xa inhibitors for the long-term management of ACS. <i>Nature Reviews Cardiology</i> , 2012, 9, 392-401.	6.1	5
442	Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2012, 9, 385-391.	6.1	19
443	Novel Oral Anticoagulation in Management of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 476-486.	0.7	1
444	Improving prevention and treatment of venous thromboembolism: clinical trial results. <i>Journal of Medical Economics</i> , 2012, 15, 611-622.	1.0	6
445	Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 499-510.	1.0	5
446	A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. <i>Thrombosis and Haemostasis</i> , 2012, 107, 916-924.	1.8	52
447	Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. <i>Thrombosis and Haemostasis</i> , 2012, 107, 379-387.	1.8	223
448	Pharmacology of Anticoagulants. <i>Disease-a-Month</i> , 2012, 58, 424-430.	0.4	8
449	The in vitro anticoagulant effect of rivaroxaban in children. <i>Thrombosis Research</i> , 2012, 130, 804-807.	0.8	37
451	Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 889-900.	1.5	4
452	Drug Interactions with Rivaroxaban following Total Joint Replacement Surgery. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1232-1238.	0.9	10
453	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681

#	ARTICLE	IF	CITATIONS
455	Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement?. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 105-106.	1.2	16
456	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management, 2012, 8, 363.	1.0	17
457	Hospital drug utilization review of dabigatran and rivaroxaban in France. Pharmacie Hospitalier Et Clinicien, 2012, 47, e1-e7.	0.3	1
458	Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry. Journal of Vascular Surgery, 2012, 56, 1045-1051.e1.	0.6	14
459	Newer Anticoagulants in Critically Ill Patients. Critical Care Clinics, 2012, 28, 427-451.	1.0	7
460	A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert Opinion on Pharmacotherapy, 2012, 13, 217-226.	0.9	8
461	Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report. Journal of Medical Case Reports, 2012, 6, 129.	0.4	20
462	Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study. Pharmaceuticals, 2012, 5, 279-296.	1.7	32
463	Venous Thromboembolism in Orthopaedic Surgery. , 0, , .		0
464	Rivaroxaban in Nonvalvular Atrial Fibrillation. Hospital Pharmacy, 2012, 47, 293-304.	0.4	1
465	New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vascular Health and Risk Management, 2012, 8, 45.	1.0	12
466	Venous thromboembolism (VTE) prevention in orthopedics: facts, controversies, and evolving management. Orthopedic Research and Reviews, 2012, , 77.	0.7	0
467	36 Antikoagulanzen. , 2012, , .		0
468	Identifying and reducing the incidence of post discharge Venous Thromboembolism (VTE) in orthopaedic patients: a systematic review.. JBI Library of Systematic Reviews, 2012, 10, 2658-2710.	0.1	2
469	Novel Oral Anticoagulants. Anesthesiology, 2012, 116, 9-11.	1.3	14
470	Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Thrombosis and Haemostasis, 2012, 107, 225-231.	1.8	22
471	Rivaroxaban and its Effect on International Normalised Ratio-A Prospective Study of 28 Hip and Knee Arthroplasty Patients. American Medical Journal, 2012, 3, 126-129.	1.0	3
472	Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thrombosis and Haemostasis, 2012, 108, 872-875.	1.8	5

#	ARTICLE	IF	CITATIONS
473	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	0.9	6
474	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.4	1,323
475	Old Versus New Oral Anticoagulants: Focus on Pharmacology. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 79-99.	4.2	71
476	Implementing the new oral anticoagulants into the hospital formulary. <i>American Journal of Hematology</i> , 2012, 87, S127-32.	2.0	12
477	Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants. <i>Clinical Cardiology</i> , 2012, 35, 730-737.	0.7	52
478	Novel Anticoagulants for Atrial Fibrillation. <i>Angiology</i> , 2012, 63, 164-170.	0.8	13
479	Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 113-121.	3.4	66
481	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 143-163.	1.0	0
482	Rivaroxaban for the prevention and treatment of venous thromboembolism. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 33-38.	1.0	3
484	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
485	Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 86-97.	1.1	47
486	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. <i>Thrombosis Journal</i> , 2013, 11, 10.	0.9	141
487	Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. <i>Thrombosis Research</i> , 2013, 132, 240-247.	0.8	13
488	New Oral Anticoagulants: Great Promise for Therapeutic Advance but Great Knowledge Gaps Remain to Be Filled. <i>Cardiology</i> , 2013, 126, 41-49.	0.6	3
489	Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 164-172.	0.4	2
490	Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3358-3366.	0.7	160
491	Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 171-182.	0.7	20
492	Bleeding and antidotes in new oral anticoagulants. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 191-202.	0.7	84

#	ARTICLE	IF	CITATIONS
493	Rivaroxaban for the Treatment of Pulmonary Embolism. <i>Advances in Therapy</i> , 2013, 30, 589-606.	1.3	13
494	Heparin concentration is critical for cell culture with human platelet lysate. <i>Cytotherapy</i> , 2013, 15, 1174-1181.	0.3	65
495	New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 141-148.	1.0	3
496	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 212-222.	1.0	29
497	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 83-97.	0.6	133
498	Stroke Prevention in Atrial Fibrillation. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 98-104.	0.6	0
499	Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2013, 23, 481-486.	0.6	34
500	Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. <i>Thrombosis Research</i> , 2013, 131, S67-S70.	0.8	4
501	A systematic update on the state of novel anticoagulants and a primer on reversal and bridging. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2013, 1, 418-426.	0.9	7
502	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	1.0	23
503	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	0.8	40
504	The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. <i>Thrombosis Research</i> , 2013, 132, 685-691.	0.8	16
505	Anticoagulant Use in Real Time. <i>Journal of Pharmacy Practice</i> , 2013, 26, 270-279.	0.5	9
506	New oral anticoagulants and regional anaesthesia. <i>British Journal of Anaesthesia</i> , 2013, 111, i96-i113.	1.5	72
508	Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?. <i>Current Emergency and Hospital Medicine Reports</i> , 2013, 1, 208-216.	0.6	3
509	The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. <i>Thrombosis Journal</i> , 2013, 11, 18.	0.9	19
510	Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell'anca e del ginocchio e nelle fratture del collo femorale: aggiornamento 2013. <i>LO SCALPELLO-OTODI Educational</i> , 2013, 27, 161-169.	0.1	0
511	Thrombotic complications after total ankle replacement. <i>Current Reviews in Musculoskeletal Medicine</i> , 2013, 6, 328-335.	1.3	10

#	ARTICLE	IF	CITATIONS
512	Practical management of new oral anticoagulants after total hip or total knee arthroplasty. <i>Musculoskeletal Surgery</i> , 2013, 97, 189-197.	0.7	11
513	The new oral anticoagulants in atrial fibrillation: an update. <i>Netherlands Heart Journal</i> , 2013, 21, 480-484.	0.3	6
514	Top 10 Clinical Research Developments in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 367.	2.1	4
515	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 817-828.	0.6	1
518	The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban—An Oral, Direct Factor Xa Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 249-255.	1.0	90
519	Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2013, 109, 154-163.	1.8	47
520	Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy. <i>British Journal of Dermatology</i> , 2013, 168, 898-899.	1.4	33
521	Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 89-98.	1.1	152
522	Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease. , 2013, , 175-237.		0
523	The Evolution of Oral Anticoagulant Therapy. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 109-134.	0.7	6
524	New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, 102-108.	0.7	45
525	Influence des nouveaux anticoagulants sur les examens de la coagulation Intéressant en clinique. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 21-27.	0.0	2
526	New Oral Anticoagulants. <i>Hospital Medicine Clinics</i> , 2013, 2, e456-e471.	0.2	0
527	Haemostatic challenges in the cancer patient: Focus on the perioperative period. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2013, 27, 493-511.	1.7	5
528	SECOT consensus on thromboembolisms in knee and hip replacement surgery. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2013, 57, 150-159.	0.1	0
530	Apixaban and Rivaroxaban Decrease Deep Venous Thrombosis But Not Other Complications After Total Hip and Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2013, 28, 1477-1481.	1.5	35
531	Anti-thrombosis effect of LRRFIP1 shRNA lentivirus in a mouse model of deep vein thrombosis. <i>Thrombosis Research</i> , 2013, 132, 127-131.	0.8	3
532	Nuevos anticoagulantes orales y su papel en la práctica clínica. <i>Revista Espanola De Cardiología Suplementos</i> , 2013, 13, 33-41.	0.2	12

#	ARTICLE	IF	CITATIONS
533	Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study. <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2013, 57, 53-60.	0.1	9
535	Rivaroxaban: An Oral Factor Xa Inhibitor. <i>Clinical Therapeutics</i> , 2013, 35, 4-27.	1.1	27
536	The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement. <i>Knee</i> , 2013, 20, 397-400.	0.8	18
537	Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty and Total Hip Arthroplasty. <i>Hospital Medicine Clinics</i> , 2013, 2, e91-e102.	0.2	0
538	Thrombin inhibitors: surgical considerations and pharmacology. <i>ANZ Journal of Surgery</i> , 2013, 83, 215-221.	0.3	8
539	Clinical management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 655-667.	0.9	19
540	Implications of new anticoagulants in primary practice. <i>International Journal of Clinical Practice</i> , 2013, 67, 139-156.	0.8	17
541	New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2013, 145, 105-112.e15.	0.6	347
542	Prevention of VTE in patients having major orthopedic surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 359-367.	1.0	26
543	Pulmonary Embolism and Deep Vein Thrombosis. , 2013, , 580-595.		1
544	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 129-141.	0.6	36
545	Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban. <i>Thrombosis Research</i> , 2013, 131, e100-e109.	0.8	78
546	Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 513-525.	1.3	16
547	Moving Toward a More Ideal Anticoagulant. <i>Chest</i> , 2013, 143, 1106-1116.	0.4	28
548	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1617-1633.	0.8	81
549	The New Oral Anticoagulants in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2013, 88, 495-511.	1.4	93
550	Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. <i>Annals of Pharmacotherapy</i> , 2013, 47, 841-855.	0.9	27
551	The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. <i>Pharmacological Research</i> , 2013, 74, 49-55.	3.1	21

#	ARTICLE	IF	CITATIONS
552	Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy. <i>Pharmacotherapy</i> , 2013, 33, 1223-1245.	1.2	18
553	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombotic-mediated conditions. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 42-55.	1.8	18
554	Anticoagulation; New Pharmacologic Methods to Prevent Venous Thromboembolism in Older Adults: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2013, 47, 605-616.	0.9	3
555	Use of New Oral Anticoagulants in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2013, 15, 331.	2.1	48
556	NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 234-243.	0.2	12
557	Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1443-1448.	1.9	20
558	The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery. <i>Pharmacotherapy</i> , 2013, 33, 1333-1340.	1.2	26
559	Incidence of neuraxial haematoma after total hip or knee surgery: <scp>RECORD</scp> programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 565-572.	0.7	33
560	Transitions of care in anticoagulated patients. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 215.	1.1	18
561	Systematic Review of Randomized Controlled Trials of New Anticoagulants for Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries, Compared With Enoxaparin. <i>Annals of Vascular Surgery</i> , 2013, 27, 355-369.	0.4	31
562	Antithrombotic Agents. , 2013, , 477-495.		2
563	Oral anticoagulants in the management of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2013, 10, 397-409.	6.1	14
564	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. <i>Clinical Research in Cardiology</i> , 2013, 102, 399-412.	1.5	179
565	Intravenous release of NO from lipidic microbubbles accelerates deep vein thrombosis resolution in a rat model. <i>Thrombosis Research</i> , 2013, 131, e31-e38.	0.8	40
567	The changing face of oral anticoagulants. <i>British Dental Journal</i> , 2013, 215, 17-20.	0.3	8
568	Thromboprophylaxis only during hospitalisation in fast-track hip and knee arthroplasty, a prospective cohort study. <i>BMJ Open</i> , 2013, 3, e003965.	0.8	91
569	Direct treatment comparison of DAbigatran and Rlvaroxaban versus NADroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA): Table 1. <i>BMJ Open</i> , 2013, 3, e002218.	0.8	6
570	Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 525-534.	0.9	2

#	ARTICLE	IF	CITATIONS
571	Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice</i> (1995), 2013, 41, 26-36.	0.5	1
572	A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention. <i>Postgraduate Medicine</i> , 2013, 125, 141-153.	0.9	23
573	Novel oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2013, 9, 849-861.	0.5	3
574	Novel Oral Anticoagulants: A Review of the Literature and Considerations in Special Clinical Situations. <i>Hospital Practice</i> (1995), 2013, 41, 8-18.	0.5	3
575	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2013, 368, 1944-1946.	13.9	28
576	The Novel Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 117-126.	1.5	28
577	Pharmacology of Antithrombotic Drugs. , 2013, , 94-109.		2
578	Treatment with novel oral anticoagulants. <i>Current Opinion in Hematology</i> , 2013, 20, 430-436.	1.2	27
579	Rivaroxaban and risk of myocardial infarction. <i>Coronary Artery Disease</i> , 2013, 24, 628-635.	0.3	44
580	Preventing venous thromboembolism in major orthopaedic surgery. <i>Current Orthopaedic Practice</i> , 2013, 24, 312-320.	0.1	0
581	Transitions of Care in Patients Receiving Oral Anticoagulants. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 54-65.	0.6	4
582	Managing New Oral Anticoagulants in the Intensive Care Unit. <i>Critical Care Nursing Quarterly</i> , 2013, 36, 390-399.	0.4	1
583	New oral therapies for the prevention and treatment of venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 113-125.	0.5	7
584	Orthopedic Surgery and Trauma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 141-160.	0.7	1
585	Pathology Consultation on Anticoagulation Monitoring. <i>American Journal of Clinical Pathology</i> , 2013, 140, 623-634.	0.4	23
586	Novel Oral Anticoagulants: A Review of New Agents. <i>Postgraduate Medicine</i> , 2013, 125, 103-114.	0.9	19
587	The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. <i>Cmaj</i> , 2013, 185, 222-227.	0.9	25
589	An Updated Review of Target-Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2013, 2, e000136.	1.6	24

#	ARTICLE	IF	CITATIONS
590	NEW ORAL ANTICOAGULANT DRUGS IN ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME. <i>Acta Medica Medianae</i> , 2013, , 42-48.	0.0	0
591	Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. <i>Annals of Internal Medicine</i> , 2013, 159, 502.	2.0	2
592	Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 270-277.	0.8	25
593	Pros and cons of new oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 464-470.	0.9	193
594	Perineural granulomatous inflammation: a potential harbinger of perineural invasion in cutaneous squamous cell carcinoma. <i>British Journal of Dermatology</i> , 2013, 168, 899-901.	1.4	1
595	Will One Size of Anticoagulant Dosage Fit All?. <i>Drug Development Research</i> , 2013, 74, 406-412.	1.4	3
596	Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 444-451.	1.9	31
597	A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 159-161.	0.7	20
598	Aspirin for the Prophylaxis of Venous Thromboembolic Events in Orthopedic Surgery Patients: A Comparison of the AAOS and ACCP Guidelines with Review of the Evidence. <i>Annals of Pharmacotherapy</i> , 2013, 47, 63-74.	0.9	70
599	Outpatient Anticoagulant Therapy. , 2013, , 698-716.		1
600	Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, 1801-1811.	1.4	81
601	The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. <i>Expert Review of Hematology</i> , 2013, 6, 677-695.	1.0	36
602	Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. <i>Anesthesiology</i> , 2013, 118, 1466-1474.	1.3	158
603	Update in General Internal Medicine: Evidence Published in 2012. <i>Annals of Internal Medicine</i> , 2013, 158, 615.	2.0	0
604	Management of severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , 2013, 30, 270-382.	0.7	740
605	Relative Effects of Two Different Enoxaparin Regimens as Comparators Against Newer Oral Anticoagulants. <i>Chest</i> , 2013, 144, 593-600.	0.4	16
606	The perioperative management of new direct oral anticoagulants: a question without answers. <i>Thrombosis and Haemostasis</i> , 2013, 110, 515-522.	1.8	76
607	Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. <i>Annals of Internal Medicine</i> , 2013, 158, 800.	2.0	176

#	ARTICLE	IF	CITATIONS
608	Prophylaxis for deep venous thrombosis and pulmonary embolism in surgery. , 0, , 234-251.		0
609	Complications Following Total Hip Arthroplasty. , 2013, , .		2
610	TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: Something new and promising, or not?. Thrombosis and Haemostasis, 2013, 109, 977-979.	1.8	0
611	Venous thrombosis/arterial thrombosis: a better understanding of pathology should help to a more appropriate choice of the therapeutic target. Sang Thrombose Vaisseaux, 2013, 25, 80-93.	0.1	0
612	Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thrombosis and Haemostasis, 2013, 110, 987-994.	1.8	21
613	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. Thrombosis and Haemostasis, 2013, 109, 1091-1098.	1.8	13
614	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vascular Health and Risk Management, 2013, 9, 207.	1.0	26
615	A new paradigm shift in antithrombotic therapy. Frontiers in Pharmacology, 2013, 4, 133.	1.6	19
616	The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Frontiers in Pharmacology, 2013, 4, 145.	1.6	15
617	Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 585-588.	1.8	12
618	Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban. Clinical Pharmacology: Advances and Applications, 2013, 5, 143.	0.8	3
619	The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty. Thrombosis, 2013, 2013, 1-5.	1.4	12
620	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Thrombosis, 2013, 2013, 1-10.	1.4	11
621	Deep Vein Thrombosis and Pulmonary Embolism. , 2013, , 247-261.		1
622	Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis?. Hamostaseologie, 2013, 33, 218-224.	0.9	3
623	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular Health and Risk Management, 2014, 10, 157.	1.0	28
624	A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clinical Pharmacology: Advances and Applications, 2014, 6, 179.	0.8	59
625	Massive human rivaroxaban overdose. Thrombosis and Haemostasis, 2014, 112, 834-836.	1.8	24

#	ARTICLE	IF	CITATIONS
626	Respiratory Review of 2014: Pulmonary Thromboembolism. Tuberculosis and Respiratory Diseases, 2014, 77, 105.	0.7	0
627	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. Thrombosis and Haemostasis, 2014, 111, 10-13.	1.8	10
628	Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome. Research Reports in Clinical Cardiology, 0, , 103.	0.2	1
630	Comparative study of the effect of rivaroxaban and fondaparinux on monocyteâ€™s coagulant activity and cytokine release. Experimental Hematology and Oncology, 2014, 3, 30.	2.0	8
631	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. BioMed Research International, 2014, 2014, 1-14.	0.9	6
632	Direct oral anticoagulants: integration into clinical practice. Postgraduate Medical Journal, 2014, 90, 529-539.	0.9	15
633	Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. Journal of Neurosurgery, 2014, 121, 1-20.	0.9	40
635	Direct Oral Anticoagulants. JACC: Cardiovascular Interventions, 2014, 7, 1333-1351.	1.1	81
636	Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial. Thrombosis Research, 2014, 134, 1198-1204.	0.8	117
637	A Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2014, 96, 177-183.	1.4	61
638	Rivaroxabanâ€™induced Epidural Hematoma and Cauda Equina Syndrome after Total Knee Arthroplasty: a Case Report. Orthopaedic Surgery, 2014, 6, 69-71.	0.7	22
639	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis Journal, 2014, 12, 24.	0.9	45
640	Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Thrombosis and Haemostasis, 2014, 112, 503-510.	1.8	10
641	The Efficacy of Rivaroxaban in Patients With Atrial Fibrillation. American Journal of Therapeutics, 2014, 21, 412-418.	0.5	2
642	Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. Hospital Practice (1995), 2014, 42, 48-61.	0.5	1
643	Perioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants. Hospital Practice (1995), 2014, 42, 62-67.	0.5	2
644	The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current Medical Research and Opinion, 2014, 30, 2151-2167.	0.9	2
645	Venous Thromboembolism and Orthopedic Surgery. , 2014, , 221-229.		0

#	ARTICLE	IF	CITATIONS
646	Risk of Gastrointestinal Bleeding with Dabigatran: A Head-to-Head Comparative Study with Rivaroxaban. <i>Digestion</i> , 2014, 90, 137-146.	1.2	19
647	The Incidence of Hematoma Formation in Patients With Continuous Femoral Catheters Following Total Knee Arthroplasty While Receiving Rivaroxaban as Thromboprophylaxis. <i>Regional Anesthesia and Pain Medicine</i> , 2014, 39, 414-417.	1.1	20
649	The 50 Highest Cited Papers in Hip and Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 1877.	1.5	40
650	The place of new oral anticoagulants in travel medicine. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 7-19.	1.5	4
651	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism: Evidence From Major Clinical Trials. <i>Seminars in Hematology</i> , 2014, 51, 121-130.	1.8	9
652	Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy. <i>Musculoskeletal Surgery</i> , 2014, 98, 21-25.	0.7	15
653	Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban. <i>Clinical Pharmacokinetics</i> , 2014, 53, 89-102.	1.6	70
654	Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. <i>International Orthopaedics</i> , 2014, 38, 169-175.	0.9	24
655	Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 299-305.	1.0	31
656	Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1-16.	1.6	420
657	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 137-149.	1.0	25
659	Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2014, 134, 449-457.	1.3	9
660	The New Era of Anticoagulation. <i>Annals of Vascular Surgery</i> , 2014, 28, 503-514.	0.4	4
661	Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 707-717.	1.1	45
662	Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X. <i>International Journal of Biological Macromolecules</i> , 2014, 65, 129-135.	3.6	49
663	Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies. <i>Thrombosis Research</i> , 2014, 133, 705-713.	0.8	37
664	Latest developments in anticoagulant drug discovery. <i>Drug Discovery Today</i> , 2014, 19, 921-935.	3.2	6
665	Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. <i>Heart</i> , 2014, 100, 550-556.	1.2	91

#	ARTICLE	IF	CITATIONS
666	Recomendações da SBA para segurança na anestesia regional em uso de anticoagulantes. Revista Brasileira De Anestesiologia, 2014, 64, 1-15.	0.6	5
668	Update on Pharmacologic Therapy for Pulmonary Embolism. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 159-169.	1.0	5
669	Antiplatelet and anticoagulation medications and the surgical patient. American Journal of Surgery, 2014, 207, 95-101.	0.9	18
670	Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. British Journal of Clinical Pharmacology, 2014, 78, 353-363.	1.1	20
671	Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. Journal of Thrombosis and Haemostasis, 2014, 12, 1626-1635.	1.9	19
672	Protocol in managing oral surgical patients taking dabigatran. Australian Dental Journal, 2014, 59, 296-301.	0.6	52
673	Extended-duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: a meta-analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis, 2014, 12, 107-109.	1.9	3
674	Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications. Drugs, 2014, 74, 1587-1603.	4.9	40
676	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular, 2014, 22, 252-258.	0.4	23
677	An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. Journal of Clinical Pharmacology, 2014, 54, 1407-1420.	1.0	42
678	Medication Pitfalls in the CKD Clinic: Case Presentations. Advances in Chronic Kidney Disease, 2014, 21, 349-354.	0.6	2
680	Management of Anticoagulation Agents in Trauma Patients. Clinics in Laboratory Medicine, 2014, 34, 563-574.	0.7	20
681	Pharmacology and Laboratory Testing of the Oral Xa Inhibitors. Clinics in Laboratory Medicine, 2014, 34, 503-517.	0.7	23
682	Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. Drugs, 2014, 74, 1209-1231.	4.9	84
683	Allogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2014, 96, 272-278.	1.4	197
684	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgraduate Medical Journal, 2014, 90, 520-528.	0.9	31
687	The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 326.	0.4	2
688	Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends. Current Reviews in Musculoskeletal Medicine, 2014, 7, 108-116.	1.3	32

#	ARTICLE	IF	CITATIONS
689	A cost-analysis model for anticoagulant treatment in the hospital setting. <i>Journal of Medical Economics</i> , 2014, 17, 492-498.	1.0	3
690	Using a combination of tranexamic acid and rivaroxaban in total knee replacements reduces transfusion requirements: A prospective cohort study. <i>Journal of Arthroscopy and Joint Surgery</i> , 2014, 1, 76-81.	0.3	3
691	Perioperative Care of the Orthopedic Patient. , 2014, , .		2
693	Recomendaciones de SBA para la seguridad en la anestesia regional en uso de anticoagulantes. <i>Brazilian Journal of Anesthesiology (Edicion En Espanol)</i> , 2014, 64, 1-15.	0.0	0
694	Patient-Reported Compliance with Thromboprophylaxis Using an Oral Factor Xa Inhibitor (Rivaroxaban) Following Total Hip and Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2014, 29, 1463-1467.	1.5	19
695	SBA Recommendations for regional anesthesia safety in patients taking anticoagulants. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2014, 64, 1-15.	0.2	6
696	The risk of infection with new oral anticoagulants: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 172, 267-268.	0.8	11
697	Succinct Review of the New VTE Prevention and Management Guidelines. <i>Mayo Clinic Proceedings</i> , 2014, 89, 394-408.	1.4	23
698	An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1077-1084.	0.7	28
699	Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 469-479.	0.6	145
700	The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 526-532.	1.0	2
701	The role of novel anticoagulants in the management of venous thromboembolism. <i>Vascular Medicine</i> , 2014, 19, 205-214.	0.8	8
702	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014, 133, S158-S166.	0.8	37
704	Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. <i>Thrombosis Research</i> , 2014, 133, 671-681.	0.8	99
705	The impact of risk assessment on the implementation of venous thromboembolism prophylaxis in foot and ankle surgery. <i>Foot and Ankle Surgery</i> , 2014, 20, 85-89.	0.8	44
706	A Systematic Review and Adjusted Indirect Comparison of Oral Anticoagulants. <i>Orthopedics</i> , 2014, 37, 763-771.	0.5	5
707	Anticoagulation in Long-Term Care: How Can We Improve Medication Monitoring?. <i>Journal of Gerontological Nursing</i> , 2014, 40, 10-15.	0.3	1
708	Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). <i>Thrombosis and Haemostasis</i> , 2014, 111, 213-225.	1.8	12

#	ARTICLE	IF	CITATIONS
709	Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2014, 112, 199-212.	1.8	8
710	A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 94-102.	1.8	74
711	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 182-212.	1.1	248
713	Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table A1. <i>European Heart Journal Supplements</i> , 2015, 17, D21-D28.	0.0	0
714	Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. <i>Current Orthopaedic Practice</i> , 2015, 26, 299-305.	0.1	3
715	Rivaroxaban for the treatment and prevention of thromboembolic disease. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 1119-1132.	1.2	13
716	Anticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 790-792.	0.2	4
717	Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates. <i>Circulation Journal</i> , 2015, 79, 331-338.	0.7	35
718	Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty. <i>Orthopedics</i> , 2015, 38, 252-263.	0.5	10
720	Regional versus general anesthesia and postoperative venous thromboembolism. , 0, , 123-128.		0
721	Anticoagulants oraux directs chez la personne âgée, point de vue de l'anesthésiste-réanimateur. <i>Les Cahiers De L'annee Gerontologique</i> , 2015, 7, 107-112.	0.0	0
722	Rivaroxaban: An Evaluation of its Cardiovascular Benefit-Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons. <i>Drugs in R and D</i> , 2015, 15, 295-306.	1.1	0
723	Combination of Superficial and Deep Blocks with Rivaroxaban. <i>Pain Medicine</i> , 2015, 16, 2024-2030.	0.9	8
724	Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data. <i>Pharmacotherapy</i> , 2015, 35, 663-669.	1.2	11
725	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	1.8	26
726	Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 231-246.	1.8	40
727	Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty. <i>Thrombosis and Haemostasis</i> , 2015, 114, 237-244.	1.8	2
728	Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach. <i>Thrombosis and Haemostasis</i> , 2015, 114, 660-669.	1.8	9

#	ARTICLE	IF	CITATIONS
729	Favorable Outcome of Rivaroxaban-Associated Intracerebral Hemorrhage Reversed by 4-Factor Prothrombin Complex Concentrate. <i>A & A Case Reports</i> , 2015, 4, 151-154.	0.7	9
730	Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1239-1249.	1.9	51
731	Thromboembolism prophylaxis failure rates after hip and knee arthroplasty. <i>Current Orthopaedic Practice</i> , 2015, 26, 277-280.	0.1	1
732	Insights into direct anticoagulants. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 492-498.	0.5	1
733	Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. <i>Journal of Hospital Medicine</i> , 2015, 10, 108-111.	0.7	35
734	Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 757-764.	0.9	22
735	Incidence and Factors Predicting Venous Thromboembolism After Surgical Treatment of Fractures Below the Hip. <i>Journal of Orthopaedic Trauma</i> , 2015, 29, e349-e354.	0.7	40
736	Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 934-939.	0.5	9
737	Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 139-147.	0.2	0
738	Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1300-1311.	1.8	6
739	Rivaroxaban: a welcome addition to anticoagulation. <i>British Journal of Cardiac Nursing</i> , 2015, 10, 346-347.	0.0	2
740	New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). <i>Nutrients</i> , 2015, 7, 9538-9557.	1.7	71
741	Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 92-96.	0.2	13
742	Portal vein thrombosis in cirrhosis: Controversies and latest developments. <i>World Journal of Gastroenterology</i> , 2015, 21, 6769-6784.	1.4	83
743	Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF- κ B Pathway. <i>International Heart Journal</i> , 2015, 56, 544-550.	0.5	31
744	Blood management strategies in lower limb arthroplasty. <i>Orthopaedics and Trauma</i> , 2015, 29, 189-194.	0.2	2
745	Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 395-401.	1.0	13
746	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.4	15

#	ARTICLE	IF	CITATIONS
747	VTE primary prevention, including hospitalised medical and orthopaedic surgical patients. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1216-1223.	1.8	11
748	Anticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature. <i>Air Medical Journal</i> , 2015, 34, 269-277.	0.3	3
749	15-Lipoxygenase and 15-hydroxyeicosatetraenoic acid regulate intravascular thrombosis in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 309, L449-L462.	1.3	16
750	Management of Bleeding Associated with New Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 788-801.	1.5	17
751	Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. <i>Thrombosis Journal</i> , 2015, 13, 27.	0.9	77
752	Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials. <i>Thrombosis Journal</i> , 2015, 13, 36.	0.9	22
753	The additional benefit of graduated compression stockings to pharmacologic thromboprophylaxis in the prevention of venous thromboembolism in surgical inpatients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 447-455.e1.	0.9	13
754	Effectiveness and safety of different duration of thromboprophylaxis in 16,865 hip replacement patients - A real-world, prospective observational study. <i>Thrombosis Research</i> , 2015, 135, 322-328.	0.8	21
755	Upregulation of MicroRNA-126 Contributes to Endothelial Progenitor Cell Function in Deep Vein Thrombosis via Its Target PIK3R2. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1613-1623.	1.2	64
756	Cost-Effective Prophylaxis Against Venous Thromboembolism After Total Joint Arthroplasty: Warfarin Versus Aspirin. <i>Journal of Arthroplasty</i> , 2015, 30, 159-164.	1.5	46
757	Venous Disorders: Medical Management. , 2015, , 1009-1034.		0
758	Risk of insomnia with non-vitamin K oral anticoagulants: systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2015, 19, 1043-1049.	0.9	1
759	The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. <i>Thrombosis Research</i> , 2015, 135, 217-225.	0.8	28
760	Thromboprophylaxis in patients undergoing total hip and knee arthroplasty: a review of current practices in an Australian teaching hospital. <i>Internal Medicine Journal</i> , 2015, 45, 293-299.	0.5	12
761	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	1.0	32
762	Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2015, 30, 1277-1280.	1.5	24
763	Evaluation of Dosing Practices of Rivaroxaban and Dabigatran. <i>Journal of Pharmacy Technology</i> , 2015, 31, 149-154.	0.5	1
764	Topical Application of Tranexamic Acid Plus Diluted Epinephrine Reduces Postoperative Hidden Blood Loss in Total Hip Arthroplasty. <i>Journal of Arthroplasty</i> , 2015, 30, 2196-2200.	1.5	30

#	ARTICLE	IF	CITATIONS
765	Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery. <i>Future Cardiology</i> , 2015, 11, 525-529.	0.5	4
766	Ecotin: Exploring a feasible antithrombotic profile. <i>International Journal of Biological Macromolecules</i> , 2015, 78, 296-303.	3.6	0
768	Which Patients May Benefit from Dose Adjustment of Non-Vitamin K Antagonist Oral Anticoagulants?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 195-207.	1.5	17
770	Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 24.	0.8	62
771	Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants. <i>JAMA Ophthalmology</i> , 2015, 133, 834.	1.4	29
772	Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 113-132.	1.5	7
773	Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 136-144.	0.5	25
774	Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery. <i>Current Rheumatology Reports</i> , 2015, 17, 25.	2.1	4
775	Venous thromboembolism: identifying patients at risk and establishing prophylaxis. <i>Current Medical Research and Opinion</i> , 2015, 31, 2297-2311.	0.9	10
776	Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 534-539.	0.8	4
777	A study on the role of rivaroxaban in management of venous thromboembolism. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 893-896.	0.1	0
778	Prevention of Venous Thromboembolism: An Evidence-Based Approach to Thromboprophylaxis. , 2015, , 123-134.		0
779	Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, doseâ€“response meta-analysis and network meta-analysis. <i>Thrombosis Research</i> , 2015, 136, 1133-1144.	0.8	55
780	Clinical development of rivaroxaban: emerging new clinical evidences?. <i>Future Cardiology</i> , 2015, 11, 565-583.	0.5	0
781	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. <i>European Heart Journal Supplements</i> , 2015, 17, D32-D41.	0.0	10
782	Prophylaxis Against Venous Thromboembolism After Total Hip and Knee Arthroplasty. <i>JBJS Reviews</i> , 2015, 3, .	0.8	9
783	Clinical Experience With Novel Oral Anticoagulants for Thromboprophylaxis After Elective Hip and Knee Arthroplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 771-778.	1.1	23
784	Peri-delivery Analgesia and Anesthesia in Women with Hemostatic or Thrombotic Disorders. , 2015, , 365-390.		0

#	ARTICLE	IF	CITATIONS
785	Handbook for Venous Thromboembolism. , 2015, , .		10
786	Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1665-1677.	1.5	3
787	Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. World Neurosurgery, 2015, 84, 1956-1961.	0.7	78
788	Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 297-308.	0.7	6
789	Pharmacology and mechanisms of action of new oral anticoagulants. Fundamental and Clinical Pharmacology, 2015, 29, 10-20.	1.0	33
790	Deep vein thrombosis after arthroplasty: Nanjing deep vein thrombosis study. Annals of Joint, 0, 1, 3-3.	1.0	0
791	New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2016, 16, 178.	0.1	1
792	Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients. Canadian Journal of Hospital Pharmacy, 2016, 69, 194-201.	0.1	12
793	Anticoagulation therapy and proximal femoral fracture treatment. EFORT Open Reviews, 2016, 1, 310-315.	1.8	12
794	The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. Vascular Health and Risk Management, 2016, 12, 209.	1.0	9
795	Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovascular Diagnosis and Therapy, 2016, 6, 570-581.	0.7	17
796	The Prophylaxis of Venous Thromboembolism. Deutsches Ärzteblatt International, 2016, 113, 532-8.	0.6	35
797	Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterology Research and Practice, 2016, 2016, 1-9.	0.7	7
798	Uso de los anticoagulantes orales directos en la prÁctica clÍnica. Revista Facultad De Medicina, 2016, 64, 295.	0.0	1
799	Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thrombosis and Haemostasis, 2016, 115, 600-607.	1.8	28
800	Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study. Annals of the Royal College of Surgeons of England, 2016, 98, 507-515.	0.3	8
801	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thrombosis and Haemostasis, 2016, 116, 42-49.	1.8	28
802	Does Anticoagulant Medication Alter Fracture-Healing? A Morphological and Biomechanical Evaluation of the Possible Effects of Rivaroxaban and Enoxaparin Using a Rat Closed Fracture Model. PLoS ONE, 2016, 11, e0159669.	1.1	12

#	ARTICLE	IF	CITATIONS
803	Recent Advances in the Pharmacological Management of Atrial Fibrillation. American Journal of Therapeutics, 2016, 23, e118-e138.	0.5	2
805	Novel anticoagulants – an update on the latest developments and management for clinicians treating patients on these drugs. Journal of Oral Pathology and Medicine, 2016, 45, 551-556.	1.4	14
806	Perioperative Management of Anticoagulation – Review of Latest Evidence. American Journal of Therapeutics, 2016, 23, e474-e484.	0.5	8
807	Anticoagulation for prosthetic heart valves. Current Opinion in Cardiology, 2016, 31, 176-182.	0.8	15
808	Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. The Cochrane Library, 2016, 2016, CD004179.	1.5	52
810	Enoxaparin and rivaroxaban have different effects on human mesenchymal stromal cells in the early stages of bone healing. Bone and Joint Research, 2016, 5, 95-100.	1.3	12
812	Fatal pulmonary embolism following elective total hip arthroplasty. Bone and Joint Journal, 2016, 98-B, 585-588.	1.9	26
813	Letter to the Editor on –Rivaroxaban Use for Thrombosis Prophylaxis is Associated With Early Periprosthetic Joint Infection–. Journal of Arthroplasty, 2016, 31, 2079.	1.5	0
814	Response to Letter to the Editor on –Rivaroxaban Use for Thromboprophylaxis Is Associated With Early Periprosthetic Joint Infection–. Journal of Arthroplasty, 2016, 31, 2079-2080.	1.5	0
815	Management of rivaroxaban in relation to bodyweight and body mass index. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 294-303.	1.0	13
816	Commentary on: Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience. Aesthetic Surgery Journal, 2016, 36, 67-70.	0.9	6
817	Evolving Treatments for Arterial and Venous Thrombosis. Circulation Research, 2016, 118, 1409-1424.	2.0	96
818	Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Seminars in Interventional Radiology, 2016, 33, 122-131.	0.3	4
819	Direct oral anticoagulants and venous thromboembolism. European Respiratory Review, 2016, 25, 295-302.	3.0	27
820	Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. Clinical Drug Investigation, 2016, 36, 1001-1010.	1.1	5
821	Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. The Cochrane Library, 2016, 9, CD005258.	1.5	64
822	An update on the pharmaceutical management of thrombosis. Expert Opinion on Pharmacotherapy, 2016, 17, 2149-2164.	0.9	7
824	Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis. Hematology/Oncology Clinics of North America, 2016, 30, 1007-1018.	0.9	5

#	ARTICLE	IF	CITATIONS
825	Prevençã³n de la enfermedad tromboemb³lica venosa en cirugÃa. EMC - Anestesia-Reanimaci³n, 2016, 42, 1-17.	0.1	1
826	Prevenzione della tromboembolia venosa in ambiente chirurgico. EMC - Anestesia-Rianimazione, 2016, 21, 1-16.	0.1	0
827	Making Tranexamic Acid the Standard of Care in Hip and Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2016, 98, e86.	1.4	1
828	Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. British Journal of Clinical Pharmacology, 2016, 81, 724-734.	1.1	17
829	Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Diseases, 2016, 22, 23-32.	1.5	39
830	Popular naturally occurring antioxidants as potential anticoagulant drugs. Chemico-Biological Interactions, 2016, 257, 35-45.	1.7	25
831	Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin. Journal of the American College of Cardiology, 2016, 68, 2272-2283.	1.2	64
832	Normal and Delayed Fracture Healing: Symphony and Cacophony. Hormone and Metabolic Research, 2016, 48, 779-784.	0.7	4
833	Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Scientific Reports, 2016, 6, 23726.	1.6	38
834	Current Anticoagulation Drugs and Mechanisms of Action. , 2016, , 33-46.		1
835	Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban. BMC Musculoskeletal Disorders, 2016, 17, 108.	0.8	9
836	Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clinical Oral Implants Research, 2016, 27, 730-733.	1.9	46
838	Pharmacological thromboprophylaxis and total hip or knee replacement. British Journal of Nursing, 2016, 25, 45-53.	0.3	4
839	Rivaroxaban Use for Thrombosis Prophylaxis Is Associated With Early Periprosthetic Joint Infection. Journal of Arthroplasty, 2016, 31, 1295-1298.	1.5	38
840	Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin. Annals of Pharmacotherapy, 2016, 50, 270-275.	0.9	21
841	Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience. Aesthetic Surgery Journal, 2016, 36, 60-66.	0.9	27
842	Danhong huayu koufuye prevents deep vein thrombosis through anti-inflammation in rats. Journal of Surgical Research, 2016, 201, 340-347.	0.8	11
843	An update on the treatment of malleolar fractures. Fuss Und Sprunggelenk, 2016, 14, 55-65.	0.1	7

#	ARTICLE	IF	CITATIONS
844	Vascular Engineering of Blood Coagulation. , 2016, , 211-219.		2
846	Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 13-26.	0.8	3
847	Vascular Engineering. , 2016, , .		6
848	Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2016, 24, 1409-1420.	2.3	71
849	Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 042-054.	1.5	18
850	Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S35-S41.	0.5	4
851	Thermodynamic models for determination of the solubility of 4-(4-aminophenyl)-3-morpholinone in different pure solvents and (1,4-dioxane + ethyl acetate) binary mixtures with temperatures from (278.15 to 333.15) K. <i>Journal of Chemical Thermodynamics</i> , 2016, 97, 214-220.	1.0	14
852	Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS). <i>Revista Española De Cirugía Ortopédica Y Traumatología</i> , 2016, 60, 44-52.	0.1	1
853	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 412-422.	0.7	28
854	Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures. <i>Aesthetic Surgery Journal</i> , 2016, 36, 440-449.	0.9	26
855	Non-Vitamin K Antagonist Oral Anticoagulants. , 2016, , .		1
856	Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. <i>Cardiology and Therapy</i> , 2016, 5, 19-41.	1.1	51
857	An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2016, 45, 618-630.	0.7	44
859	Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 37-44.e1.	0.4	91
860	Measurement and correlation of the solubility of rivaroxaban (form I) in binary mixtures of ethyl acetate with tetrahydrofuran, N,N-dimethylformamide, and N,N-dimethylacetamide from T=(278.15 to) Tj ETQq0 0 0ogBT /Overlock 10		
861	Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 138-146.	0.7	18
862	Hypercoagulable state evaluated by thromboelastography in patients with idiopathic membranous nephropathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 321-327.	1.0	11
863	Pulmonary Thromboembolism. , 2016, , 1001-1030.e10.		3

#	ARTICLE	IF	CITATIONS
864	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <i>Europace</i> , 2016, 18, 955-964.	0.7	62
865	Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 102-104.	0.5	12
866	Stacked Modalities' Thromboprophylactic Therapy for Patients Undergoing Total Knee Replacement Surgery. <i>Journal of Knee Surgery</i> , 2017, 30, 218-222.	0.9	2
867	Lipid-based carriers for controlled delivery of nitric oxide. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1341-1353.	2.4	30
868	Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 85-93.	3.7	38
870	Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1466-1475.	1.1	48
871	Rivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 515-523.	0.9	21
872	Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. <i>Pharmacoeconomics</i> , 2017, 35, 517-535.	1.7	16
873	Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?. <i>American Journal of Medicine</i> , 2017, 130, 900-906.	0.6	6
874	Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. <i>Journal of Arthroplasty</i> , 2017, 32, 2911-2919.e6.	1.5	29
875	Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1674-1683.e3.	2.4	109
876	Direct anticoagulants and nursing: An approach from patient's safety. <i>Enfermería Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.1	1
877	The efficacy and safety of epinephrine for postoperative bleeding in total joint arthroplasty. <i>Medicine (United States)</i> , 2017, 96, e6763.	0.4	9
878	Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. <i>Clinical and Translational Science</i> , 2017, 10, 260-270.	1.5	15
879	Lower limb immobilisation and venous thromboembolism risk: combined case-control studies. <i>Postgraduate Medical Journal</i> , 2017, 93, 354-359.	0.9	14
880	Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 562-569.	1.0	10
881	Anticoagulantes directos y Enfermería: un abordaje desde la seguridad clínica. <i>Enfermería Clínica</i> , 2017, 27, 106-112.	0.1	1
882	Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 967-972.	0.7	11

#	ARTICLE	IF	CITATIONS
883	The role of new oral anticoagulants in orthopaedics: an update of recent evidence. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2017, 27, 573-582.	0.6	12
884	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
885	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 237-245.	0.6	11
886	Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. <i>Advances in Therapy</i> , 2017, 34, 466-480.	1.3	11
887	Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. <i>Pharmacotherapy</i> , 2017, 37, 170-176.	1.2	5
888	Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty. <i>Medicine (United States)</i> , 2017, 96, e8059.	0.4	5
889	Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. <i>Journal of Orthopaedics</i> , 2017, 14, 537-543.	0.6	29
890	Surgical trial design "learning curve and surgeon volume. <i>Bone and Joint Research</i> , 2017, 6, 194-195.	1.3	21
891	Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 1999-2020.	1.1	6
892	Can patients with femoral neck fracture benefit from preoperative thromboprophylaxis?. <i>Medicine (United States)</i> , 2017, 96, e7604.	0.4	10
894	Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures. <i>Journal of Vascular Surgery</i> , 2017, 66, 1143-1148.	0.6	9
895	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	1.0	23
896	Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. <i>Current Opinion in Hematology</i> , 2017, 24, 453-459.	1.2	4
897	Venous Thromboembolism Prophylaxis in Total Hip Arthroplasty and Total Knee Arthroplasty Patients. <i>Journal of the American Academy of Orthopaedic Surgeons, The</i> , 2017, 25, 789-798.	1.1	46
898	Tranexamic acid versus fibrin sealant in primary total hip replacement: a comparative study. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2017, 27, 923-928.	0.6	4
899	Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban. <i>American Journal of Medicine</i> , 2017, 130, 1024-1032.	0.6	30
900	Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided. <i>Journal of Arthroplasty</i> , 2017, 32, 980-986.	1.5	36
901	Evaluation of an oral direct factor Xa inhibitor anticoagulant in healthy adult horses. <i>Journal of Veterinary Emergency and Critical Care</i> , 2017, 27, 82-88.	0.4	3

#	ARTICLE	IF	CITATIONS
902	Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 139-148.	1.0	9
903	Allogeneic Blood Transfusion Is a Significant Risk Factor for Surgical-Site Infection Following Total Hip and Knee Arthroplasty: A Meta-Analysis. <i>Journal of Arthroplasty</i> , 2017, 32, 320-325.	1.5	160
904	A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor. <i>Journal of Arthroplasty</i> , 2017, 32, 958-964.	1.5	9
905	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. <i>Journal of Arthroplasty</i> , 2017, 32, 645-652.	1.5	53
906	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	1.8	53
907	Fatal pulmonary thromboembolism after Achilles tendon open repair. <i>Medicine (United States)</i> , 2017, 96, e8887.	0.4	1
909	Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition). <i>Regional Anesthesia and Pain Medicine</i> , 2017, 43, 1.	1.1	117
910	The benefit of pharmacological venous thromboprophylaxis in foot and ankle surgery. <i>South African Medical Journal</i> , 2017, 107, 327.	0.2	13
911	Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy. <i>Journal of Osteopathic Medicine</i> , 2017, 117, 7-15.	0.4	18
912	Non-hemorrhage-related adverse effects of rivaroxaban. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017, 2, 108-112.	0.5	14
913	Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. <i>Orthopedic Research and Reviews</i> , 2017, Volume 9, 1-11.	0.7	4
914	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017, 1, 1827-1838.	2.5	50
915	Nuevos anticoagulantes orales: actualizaci3n. <i>Revista Chilena De CardiologÃa</i> , 2017, 36, 254-263.	0.0	3
916	Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. <i>International Angiology</i> , 2017, 36, 1-20.	0.4	108
917	Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. <i>New England Journal of Medicine</i> , 2018, 378, 699-707.	13.9	294
918	Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2018, 33, S131-S135.	1.5	63
919	Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty. <i>Journal of Knee Surgery</i> , 2018, 31, 605-609.	0.9	6
920	Fractures in the Elderly. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
921	Direct Oral Anticoagulants. , 2018, , 87-103.		0
922	Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 309-320.	1.3	51
923	What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants. JAMA Surgery, 2018, 153, 577.	2.2	29
924	The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease. Thrombosis and Haemostasis, 2018, 118, S2-S11.	1.8	1
925	Cardiovascular Drugs and Hemostasis. , 2018, , 561-589.		0
926	New Trends in Anticoagulation Therapy. Surgical Clinics of North America, 2018, 98, 219-238.	0.5	21
927	Anticoagulantes orales directos: puesta al día. Medicina Clínica, 2018, 151, 198-206.	0.3	23
929	Anticlotting agents and the surgical management of glaucoma. Current Opinion in Ophthalmology, 2018, 29, 185-189.	1.3	5
930	Extrahepatic Portal Vein Obstruction: Asian and Global Perspective. , 2018, , 271-300.		0
931	Peri-Procedural Management of Oral Anticoagulants in the DOAC Era. Progress in Cardiovascular Diseases, 2018, 60, 600-606.	1.6	25
933	Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. Thrombosis and Haemostasis, 2018, 118, S34-S44.	1.8	1
934	Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study. Journal of International Medical Research, 2018, 46, 1936-1946.	0.4	9
935	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	1.0	1,576
936	Neuromuscular electrical stimulation for the prevention of venous thromboembolism. Phlebology, 2018, 33, 367-378.	0.6	18
937	Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. Journal of Pharmacy Practice, 2018, 31, 202-207.	0.5	15
938	Increased Incidence of Bleeding and Wound Complications With Factor-Xa Inhibitors After Total Joint Arthroplasty. Journal of Arthroplasty, 2018, 33, 533-536.	1.5	26
939	European guidelines on perioperative venous thromboembolism prophylaxis. European Journal of Anaesthesiology, 2018, 35, 96-107.	0.7	15
940	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	6.3	651

#	ARTICLE	IF	CITATIONS
941	Antithrombotic Stewardship: Assessing Use of Computerized Clinical Decision Support Tools to Enhance Safe Prescribing of Direct Oral Anticoagulants in Hospitalized Patients. <i>Journal of Patient Safety</i> , 2021, 17, e1057-e1061.	0.7	6
942	Routine coagulation test abnormalities caused by rivaroxaban. <i>Medicine (United States)</i> , 2018, 97, e13104.	0.4	3
943	Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events. <i>Thrombosis Journal</i> , 2018, 16, 26.	0.9	3
944	Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2152-2161.	1.8	55
945	A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism. <i>Clinical Therapeutics</i> , 2018, 40, 2140-2167.	1.1	15
946	Venous thromboembolism after total joint arthroplasty: Risk stratification and prophylaxis. <i>Seminars in Arthroplasty</i> , 2018, 29, 200-204.	0.3	1
947	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
948	Use of oral anticoagulants for the prevention of thromboembolic events in the post-operative period of hip arthroplasty: a systematic review. <i>Revista Brasileira De Ortopedia</i> , 2018, 53, 515-520.	0.6	2
949	Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey. <i>Transfusion</i> , 2018, 58, 3014-3026.	0.8	5
950	Pulmonary Embolism While on Aspirin for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty. <i>Journal of Primary Care and Community Health</i> , 2018, 9, 215013271879744.	1.0	0
951	The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 117S-126S.	0.7	11
952	The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 1890-1896.	1.0	31
953	Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 322.	0.8	20
954	The practice pattern of anticoagulation prophylaxis for patients undergoing total hip replacement in a major orthopaedic centre; a retrospective review. <i>HIP International</i> , 2018, 28, 178-181.	0.9	0
955	Direct oral anticoagulants: An update. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 198-206.	0.1	15
956	Thromboembolism prophylaxis in orthopaedics: an update. <i>EFORT Open Reviews</i> , 2018, 3, 136-148.	1.8	142
957	Methods of DVT Prophylaxis after Total Knee Arthroplasty. , 2018, , .		0
958	Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 803-809.	0.9	9

#	ARTICLE	IF	CITATIONS
959	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. <i>Journal of Clinical Medicine</i> , 2018, 7, 29.	1.0	29
960	Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1315-1321.	0.7	33
961	Rivaroxaban-Associated Intraparenchymal Hemorrhage Managed with 4-Factor Prothrombin Complex Concentrate. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 62-68.	0.6	1
962	Risk of Venous Thromboembolism in Surgical Elderly Patients. , 2018, , 65-78.		0
963	The effectiveness of graduated compression stockings for prevention of venous thromboembolism in orthopedic and abdominal surgery patients requiring extended pharmacologic thromboprophylaxis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2018, 6, 766-777.e2.	0.9	13
964	A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease. <i>Indian Heart Journal</i> , 2018, 70, 911-914.	0.2	3
965	Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients. <i>Patient Safety in Surgery</i> , 2018, 12, 22.	1.1	2
966	Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 501-514.	0.6	2
968	Centers for Disease Control and Prevention 2017 Guidelines for Prevention of Surgical Site Infections: Review and Relevant Recommendations. <i>Current Reviews in Musculoskeletal Medicine</i> , 2018, 11, 357-369.	1.3	33
969	Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016â€“2017. <i>Internal and Emergency Medicine</i> , 2019, 14, 355-363.	1.0	1
970	Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLCâ€“MS/MS and Its Application to A Pharmacokinetic Interaction Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 229-236.	0.6	8
971	Direct-Acting Oral Anticoagulants in Critically Ill Patients. <i>Chest</i> , 2019, 156, 604-618.	0.4	11
972	The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population. <i>Journal of Surgical Research</i> , 2019, 244, 509-515.	0.8	9
973	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 805-814.	1.3	9
974	Human Platelet Lysate Sustains the Osteogenic/Adipogenic Differentiation Potential of Adipose-Derived Mesenchymal Stromal Cells and Maintains Their DNA Integrity in vitro. <i>Cells Tissues Organs</i> , 2019, 207, 149-164.	1.3	9
975	Thromboembolism in major joint prosthetic surgery: False or fact. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1623-1625.	1.9	0
976	Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. <i>Orthopaedic Surgery</i> , 2019, 11, 886-894.	0.7	12
977	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	1.0	17

#	ARTICLE	IF	CITATIONS
978	<p>Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis</p>. Clinical Epidemiology, 2019, Volume 11, 911-921.	1.5	27
979	Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. Journal of Arthroplasty, 2019, 34, 789-800.e6.	1.5	13
980	Venous Thromboembolism Chemoprophylaxis in Total Hip and Knee Arthroplasty. JBJS Reviews, 2019, 7, e2-e2.	0.8	6
981	Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children postÁFontan procedure: Rationale and design of a prospective, randomized trial (the Tj ETQq1 1 0.784314 rgBT /Oerlock	0.1	0
982	Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis. Value in Health, 2019, 22, 953-969.	0.1	6
983	O que mudou nas Áltimas dÁcadadas na profilaxia do tromboembolismo venoso em pacientes internados: artigo de revisÁo. Jornal Vascular Brasileiro, 2019, 18, e20180021.	0.1	5
985	Changes in renal function and occurrence of contrast-induced nephropathy after percutaneous coronary interventions in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants or warfarin. Postepy W Kardiologii Interwencyjnej, 2019, 15, 59-67.	0.1	2
986	Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2019, 48, 439-453.	1.0	20
987	Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. American Journal of Health-System Pharmacy, 2019, 76, S55-S60.	0.5	4
988	The case for extended thromboprophylaxis in medically hospitalised patients Á not yet made. European Journal of Preventive Cardiology, 2019, , 204748731983657.	0.8	2
989	Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist. American Journal of Physical Medicine and Rehabilitation, 2019, 98, e40-e42.	0.7	0
990	Aspirin for venous thromboembolism prophylaxis after hip or knee arthroplasty: An updated meta-analysis of randomized controlled trials. Journal of Orthopaedics, 2019, 16, 294-302.	0.6	16
992	Operative spinal trauma: Thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant. Journal of Thrombosis and Haemostasis, 2019, 17, 925-933.	1.9	22
993	Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. American Journal of Cardiovascular Drugs, 2019, 19, 525-539.	1.0	8
994	Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-8.	0.8	23
995	No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA. Clinical Orthopaedics and Related Research, 2019, 477, 396-402.	0.7	27
996	Use of modified intention-to-treat analysis in studies of direct oral anticoagulants and risk of selection bias: a systematic review. BMJ Evidence-Based Medicine, 2019, 24, 63-69.	1.7	1
997	Rivaroxaban for prevention and treatment of venous thromboembolism. Future Cardiology, 2019, 15, 63-77.	0.5	7

#	ARTICLE	IF	CITATIONS
998	American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. <i>Blood Advances</i> , 2019, 3, 3898-3944.	2.5	299
999	The top 100 most cited articles on total hip arthroplasty: a bibliometric analysis. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 412.	0.9	38
1000	CORR Insights®: Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery: Findings from the Swedish Registry. <i>Clinical Orthopaedics and Related Research</i> , 2019, 477, 1344-1346.	0.7	0
1001	The necessity of routine postoperative laboratory tests in enhanced recovery after surgery for primary hip and knee arthroplasty. <i>Medicine (United States)</i> , 2019, 98, e15513.	0.4	13
1002	Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery: Findings from the Swedish Registry. <i>Clinical Orthopaedics and Related Research</i> , 2019, 477, 1335-1343.	0.7	7
1003	Application of thrombelastography in primary total knee and total hip replacement. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 281-290.	0.5	8
1004	Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2019, 29, 455-460.	0.6	11
1005	Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study. <i>Pharmacological Research</i> , 2019, 141, 201-207.	3.1	11
1006	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€”Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
1007	The Effect of BMI and Gender on Bleeding Events when Rivaroxaban Is Administered for Thromboprophylaxis Following Total Hip and Total Knee Arthroplasty. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 180-186.	1.5	8
1008	General Assembly, Prevention, Postoperative Factors: Proceedings of International Consensus on Orthopedic Infections. <i>Journal of Arthroplasty</i> , 2019, 34, S169-S174.	1.5	9
1009	Direct Oral Anticoagulants vs Low-Molecularâ€”Weight Heparin for Thromboprophylaxis in Nonoperative Pelvic Fractures. <i>Journal of the American College of Surgeons</i> , 2019, 228, 89-97.	0.2	15
1010	Outpatient Oral Anticoagulant Therapy. , 2019, , 747-777.		1
1011	Preventive Effects of Different Drugs on Asymptomatic Lower Extremities Deep Venous Thrombosis After Artificial Joint Replacement: A Mixed Treatment Comparison. <i>American Journal of Therapeutics</i> , 2019, 26, e45-e53.	0.5	5
1012	Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?. <i>HIP International</i> , 2020, 30, 564-571.	0.9	11
1013	Dental Implant Treatment in Medically Compromised Patients. , 2020, , .		1
1014	Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 792-799.e61.	2.4	54
1015	Mechanical prophylaxis, early mobilisation and risk stratification: as effective as drugs for low risk patients undergoing primary joint replacement. Results in 13,384 patients. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 219-225.	0.8	8

#	ARTICLE	IF	CITATIONS
1016	Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review. <i>Journal of Orthopaedics</i> , 2020, 19, 166-173.	0.6	1
1017	Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. <i>European Journal of Internal Medicine</i> , 2020, 72, 53-59.	1.0	8
1018	Effects of Rivaroxaban on Platelet Aggregation. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 180-184.	0.8	4
1019	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	2.5	636
1021	A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile. <i>Journal of Arthroplasty</i> , 2020, 35, 3093-3098.	1.5	13
1022	Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. <i>Value in Health Regional Issues</i> , 2020, 23, 105-111.	0.5	2
1023	Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin. <i>Journal of Orthopaedic Surgery</i> , 2020, 28, 230949902093886.	0.4	4
1024	Therapeutic duplication of anticoagulants: a retrospective study of frequency and consequences in a tertiary referral hospital. <i>Thrombosis Journal</i> , 2020, 18, 14.	0.9	5
1025	Prevention, diagnosis, and management of venous thromboembolism in the critically ill surgical and trauma patient. <i>Current Opinion in Critical Care</i> , 2020, 26, 640-647.	1.6	10
1026	Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, 971-981.	1.1	122
1027	Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized with Acute Coronary Syndrome. <i>Cardiovascular Drugs and Therapy</i> , 2020, , 1.	1.3	1
1028	Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 733-741.	0.6	8
1029	Effect of 3 different anticoagulants on hidden blood loss during total hip arthroplasty after tranexamic acid. <i>Medicine (United States)</i> , 2020, 99, e22028.	0.4	2
1030	Patients Taking Direct Oral Anticoagulants (DOAC) Undergoing Oral Surgery: A Review of the Literature and a Proposal of a Peri-Operative Management Protocol. <i>Healthcare (Switzerland)</i> , 2020, 8, 281.	1.0	8
1031	Updates on the use of direct oral anticoagulants for the management of chronic conditions. <i>Pharmacy Today</i> , 2020, 26, 44-58.	0.0	0
1032	Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e914-e931.	1.6	77
1033	SBA 2020: Regional anesthesia guideline for using anticoagulants update. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2020, 70, 364-387.	0.2	1
1034	Temporal trends in pharmacologic prophylaxis for venous thromboembolism after hip and knee replacement in older adults. <i>Vascular Medicine</i> , 2020, 25, 450-459.	0.8	2

#	ARTICLE	IF	CITATIONS
1036	Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 849.e19-849.e23.	0.8	6
1037	Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 718-723.	1.0	5
1038	How do I manage the morbidly obese critically ill patient?. , 2020, , 186-198.e1.		0
1039	Prevention of thrombosis. , 2020, , 59-104.		0
1040	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism Following Surgery for Hip Fracture in Older Adults: A Population-Based Cohort Study. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2020, 11, 215145931989752.	0.6	10
1041	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.	1.0	6
1042	Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 853-860.	1.0	7
1043	Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents. <i>Thrombosis Research</i> , 2020, 190, 103-111.	0.8	14
1044	Venous thromboembolism in trauma patients with lower limb cast immobilization, associated risk reduction and complication using rivaroxaban. <i>Irish Journal of Medical Science</i> , 2021, 190, 169-175.	0.8	3
1045	Safety of Rivaroxaban for Postoperative Venous Thromboembolism Prophylaxis Following Abdominal Body Contouring Surgery: 600 Patients. <i>Aesthetic Surgery Journal</i> , 2021, 41, 674-681.	0.9	6
1046	The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition?. <i>Artificial Organs</i> , 2021, 45, E123-E129.	1.0	6
1047	Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence. <i>Clinical and Translational Oncology</i> , 2021, 23, 1034-1046.	1.2	3
1048	Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures. <i>Journal of Surgical Research</i> , 2021, 258, 324-331.	0.8	13
1049	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 283-297.	1.0	9
1050	Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers. <i>Thrombosis Update</i> , 2021, 2, 100038.	0.4	3
1051	Risque thromboembolique veineux chez les patients traumatisés d'un membre inférieur nécessitant une immobilisation : vers une approche individualisée. <i>Annales Francaises De Medecine D'Urgence</i> , 2021, 11, 311-319.	0.0	0
1053	Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review. <i>Cardiovascular Therapeutics</i> , 2021, 2021, 1-9.	1.1	15
1054	Expert Consensus Decision Pathway of the American College of Cardiology on Management of Bleeding in Patients With Oral Anticoagulants: A Review of the 2020 Update for Perioperative Physicians. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2471-2479.	0.6	5

#	ARTICLE	IF	CITATIONS
1055	Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? A systematic review and network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e50-e58.	0.8	25
1056	Venous Thromboembolism and Bleeding Events With Chemoprophylaxis in Abdominoplasty: A Systematic Review and Pooled Analysis of 1596 Patients. <i>Aesthetic Surgery Journal</i> , 2021, 41, 1279-1289.	0.9	5
1057	Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2022, 269, 664-675.	1.8	14
1058	Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. <i>Journal of Personalized Medicine</i> , 2021, 11, 250.	1.1	9
1059	The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. <i>Medicine (United States)</i> , 2021, 100, e25216.	0.4	10
1060	Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery. <i>Postgraduate Medicine</i> , 2021, 133, 20-26.	0.9	7
1061	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1010-1026.	1.0	10
1062	Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. <i>Thrombosis Research</i> , 2021, 199, 43-53.	0.8	7
1063	Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis. <i>Knee Surgery and Related Research</i> , 2021, 33, 10.	1.8	11
1064	Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. <i>Pharmacological Research</i> , 2021, 166, 105438.	3.1	9
1065	The Effectiveness and Safety of Direct Oral Anticoagulants Following Lower Limb Fracture Surgery: A Systematic Review and Meta-analysis. <i>Journal of Orthopaedic Trauma</i> , 2021, 35, 217-224.	0.7	8
1066	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
1067	Thromboprophylaxis across orthopaedic surgery: Bibliometric analysis of the most cited articles. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2021, 16, 157-167.	0.6	3
1069	Reply to the Letter by Laurent Auboire. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2021, 107, 102880.	0.9	0
1070	Comments on: "Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program" by JY Jenny, Y Bulaid, P Boisrenoult, N Bonin, P Henky, et al. published in <i>Orthop Traumatol Surg Res</i> 2020;106:1533-1538. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2021, 107, 102878.	0.9	0
1071	Réponse à la lettre de Laurent Auboire. <i>Revue De Chirurgie Orthopedique Et Traumatologique</i> , 2021, 107, 392-393.	0.0	0
1072	Proposition: "Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program" de JY Jenny, Y Bulaid, P Boisrenoult, N Bonin, P Henky, et al. Publié dans <i>Orthop Traumatol Surg Res</i> 2020;106:1533-1538. <i>Revue De Chirurgie Orthopedique Et Traumatologique</i> , 2021, 107, 392.	0.0	0
1073	Rivaroxaban for the prevention of venous thromboembolism after radiofrequency ablation of saphenous veins concomitant with miniphlebectomy, sclerotherapy, or no treatment of varicose tributaries. <i>Phlebology</i> , 2021, 36, 741-751.	0.6	7

#	ARTICLE	IF	CITATIONS
1074	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 724-734.	1.5	3
1075	Rotational Thromboelastometry Findings Are Associated with Symptomatic Venous Thromboembolic Complications after Hip Fracture Surgery. <i>Clinical Orthopaedics and Related Research</i> , 2021, 479, 2457-2467.	0.7	27
1076	Efficacy and safety of anticoagulants for postoperative thromboprophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0250096.	1.1	8
1077	Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry. <i>Journal of Arthroplasty</i> , 2021, 36, 2068-2075.e2.	1.5	10
1078	A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision. <i>Pharmacotherapy</i> , 2021, 41, 608-615.	1.2	7
1079	Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2021, 103, 1556-1564.	1.4	15
1080	Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	1
1081	Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 3. Pharmacological venous thromboembolism prophylaxis. <i>Knee Surgery and Related Research</i> , 2021, 33, 24.	1.8	11
1082	Edoxaban in Cardiovascular Disease Management: Review. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	2
1083	Edoxaban (LIXIANA®) in the treatment of venous thromboembolism. <i>Future Cardiology</i> , 2021, 17, 779-791.	0.5	1
1084	Postoperative Bleeding Complications in Patients on Novel Oral Anticoagulants and Vitamin K Antagonist Following an Invasive Dental Procedure - A Review of Literature. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021, 10, 3047-3052.	0.1	0
1085	Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms. <i>Thrombosis Journal</i> , 2021, 19, 63.	0.9	12
1086	Application of thromboelastography in comparing coagulation difference of rivaroxaban and enoxaparin for thromboprophylaxis after total hip arthroplasty. <i>Journal of Orthopaedic Surgery</i> , 2021, 29, 230949902110426.	0.4	2
1087	A Review of Current and Future Antithrombotic Strategies in Surgical Patients "Leaving the Graduated Compression Stockings Behind?". <i>Journal of Clinical Medicine</i> , 2021, 10, 4294.	1.0	5
1088	Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10524.	1.8	19
1089	Major Orthopedic Surgery. , 2022, , 521-529.		0
1090	Cardiovascular Drugs and Hemostasis. , 2022, , 701-729.		1
1091	Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty. <i>Medicine (United States)</i> , 2021, 100, e23814.	0.4	0

#	ARTICLE	IF	CITATIONS
1092	Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. Chinese Medical Journal, 2021, 134, 164-172.	0.9	11
1093	New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban. , 2013, , 67-79.		1
1094	General Perioperative Complications. , 2014, , 23-105.		1
1095	Venous Thromboembolism Prophylaxis in the Patient with Rheumatic Diseases Undergoing Orthopedic Surgery. , 2013, , 45-56.		1
1097	Drug-Induced Disorders and Dental Implant Treatment. , 2020, , 149-183.		2
1099	Antithrombotika und AntihÄmorrhagika. , 2012, , 425-445.		2
1100	Antithrombotika und AntihÄmorrhagika. , 2013, , 413-433.		1
1101	Antithrombotika und AntihÄmorrhagika. , 2015, , 477-500.		1
1102	Antithrombotika und AntihÄmorrhagika. , 2016, , 351-368.		2
1103	Antithrombotika und AntihÄmorrhagika. , 2017, , 353-372.		1
1104	Anticoagulants and neuraxial and peripheral nerve blocks. , 2011, , 629-640.		1
1107	The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 123-129.	3.4	51
1108	Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study. PLoS ONE, 2017, 12, e0178214.	1.1	28
1109	Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis. PLoS ONE, 2017, 12, e0186449.	1.1	10
1111	Novos anticoagulantes para a profilaxia do tromboembolismo venoso em cirurgias ortopÄ©dicas de grande porte. Jornal Vascular Brasileiro, 2011, 10, 145-153.	0.1	9
1112	Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. Current Vascular Pharmacology, 2011, 9, 763-769.	0.8	22
1113	A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale. JMIR Research Protocols, 2014, 3, e73.	0.5	12
1114	The evolution of anticoagulant therapy. Blood Transfusion, 2016, 14, 175-84.	0.3	53

#	ARTICLE	IF	CITATIONS
1115	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. <i>Blood Transfusion</i> , 2016, 14, 23-65.	0.3	78
1116	Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. <i>Health Technology Assessment</i> , 2009, 13, 43-8.	1.3	23
1117	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-220.	1.3	26
1118	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-386.	1.3	117
1120	Current status of rivaroxaban in elderly patients with pulmonary embolism (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2817-2825.	0.8	8
1121	Rivaroxaban treatment for young patients with pulmonary embolism (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 694-704.	0.8	2
1122	Unanswered Questions, Unmet Needs in Venous Thromboprophylaxis. <i>Orthopedics</i> , 2009, 32, 62-66.	0.5	10
1123	New Oral Anticoagulants for Thromboprophylaxis After Total Hip or Knee Arthroplasty. <i>Orthopedics</i> , 2009, 32, 79-84.	0.5	22
1124	Limit the Bleeding, Limit the Pain in Total Hip and Knee Arthroplasty. <i>Orthopedics</i> , 2010, 33, 11-13.	0.5	46
1125	New Oral Antithrombotic Agents for the Prevention of Deep Venous Thrombosis and Pulmonary Embolism in Orthopedic Surgery. <i>Orthopedics</i> , 2010, 33, 27-32.	0.5	2
1126	Never Events and Related Quality Measures Following Total Hip and Total Knee Replacement. <i>Orthopedics</i> , 2010, 33, 838-842.	0.5	7
1127	Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. <i>Orthopedics</i> , 2011, 34, 795-804.	0.5	14
1128	Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis. <i>Orthopedics</i> , 2012, 35, e932-8;discussion e939.	0.5	8
1129	Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland. <i>Orthopedics</i> , 2017, 40, 109-116.	0.5	10
1130	The Role of Intraoperative Intermittent Pneumatic Compression Devices in Venous Thromboembolism Prophylaxis in Total Hip and Total Knee Arthroplasty. <i>Orthopedics</i> , 2018, 41, e98-e103.	0.5	10
1131	Comparison of switch therapy modalities (enoxaparine to rivaroxaban or dabigatran) with enoxaparine alone after hip and knee replacement; a non-blinded, randomised study. <i>Acta Orthopaedica Et Traumatologica Turcica</i> , 2015, 49, 255-9.	0.3	10
1132	An algorithm for managing warfarin resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 724-730.	0.6	32
1133	When patients on target-specific oral anticoagulants need surgery. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 629-639.	0.6	8

#	ARTICLE	IF	CITATIONS
1134	Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience. <i>Cardiology Research</i> , 2013, 4, 207-210.	0.5	7
1135	Nye perorale antikoagulasjonsmidler – en oversikt. <i>Tidsskrift for Den Norske Lægeforening</i> , 2013, 133, 1940-1945.	0.2	8
1136	Nuevos anticoagulantes orales. <i>Revista Medica De Chile</i> , 2011, 139, 1347-1355.	0.1	8
1137	Oral and parenteral anticoagulants. <i>Journal of Postgraduate Medicine</i> , 2012, 58, 275-285.	0.2	10
1138	Newer antithrombotic drugs. <i>Indian Journal of Critical Care Medicine</i> , 2010, 14, 188-195.	0.3	26
1139	Novel oral anticoagulants: A new era in anti-thrombotic therapy. <i>Ibnosina Journal of Medicine and Biomedical Sciences</i> , 2013, 5, 247.	0.2	1
1140	Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation. <i>Indian Journal of Anaesthesia</i> , 2017, 61, 712.	0.3	10
1141	Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience. <i>World Journal of Hepatology</i> , 2020, 12, 207-219.	0.8	4
1142	Dabigatran and rivaroxaban, new oral anticoagulants. New approaches in Dentistry. <i>Journal of Clinical and Experimental Dentistry</i> , 2010, , e1-e5.	0.5	7
1143	Anticoagulant treatment: the end of the old agents?. <i>Swiss Medical Weekly</i> , 2012, 142, w13684.	0.8	6
1144	Direct oral anticoagulants: a guide for daily practice. <i>Swiss Medical Weekly</i> , 2016, 146, w14286.	0.8	11
1145	New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. <i>World Journal of Orthopedics</i> , 2014, 5, 188.	0.8	5
1146	The New AAOS Clinical Practice Guidelines on Venous Thromboembolic Prophylaxis: How To Adapt Them to Your Practice. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2011, 19, 717-721.	1.1	17
1147	Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty. <i>Hamostaseologie</i> , 2015, 35, 358-363.	0.9	6
1150	Diagnosis and Management for deep vein thrombosis and pulmonary thromboembolism. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 478-484.	0.1	1
1153	Neue Arzneimittel 2008. , 2009, , 45-108.		0
1155	In the Pipeline: New Oral Anticoagulants for the Prevention of Venous Thromboembolism. <i>Orthopedics</i> , 2009, 32, 35.	0.5	0
1156	New Anticoagulants: Anti-IIa or Anti-Xa agents?. , 2009, , 763-768.		0

#	ARTICLE	IF	CITATIONS
1157	New Anticoagulants: Anti-IIa or Anti-Xa Agents?. , 2009, , 763-768.		0
1158	Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. , 2009, , 29-38.		1
1159	FXa inhibitors : Updates on clinical trial. Japanese Journal of Thrombosis and Hemostasis, 2009, 20, 527-533.	0.1	0
1162	Oral Direct Factor Xa Inhibitors. Fundamental and Clinical Cardiology, 2009, , 307-326.	0.0	0
1163	Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technology Assessment, 2009, 13, 43-48.	1.3	6
1164	The comparative efficacy of Rivaroxaban and Enoxaparin for preventing the formation of thrombi after hip joint arthroplasty. Ortopediia, Travmatologija i Protezirovanie, 2009, .	0.0	0
1165	New oral anticoagulants. , 2010, , 43-70.		0
1167	La prÃ©vention thrombo-embolique en chirurgie orthopÃ©dique et traumatologique majeure. , 2010, , 269-278.		0
1168	Venous Thromboembolism in the Elderly. , 2010, , 356-361.		0
1169	Our experience of using oral anticoagulant Rivaroxaban in patients after cementless hip joint arthroplasty. Ortopediia, Travmatologija i Protezirovanie, 2010, .	0.0	0
1170	Thromboprophylaxis for hip and knee surgery: critical appraisal of rivaroxaban. Open Access Surgery, 0, , 27.	0.4	0
1171	Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice. F1000 Medicine Reports, 2010, 2, .	2.9	0
1172	Hematologic Disorders in the Elderly. , 2011, , 207-219.		0
1175	Thromboprophylaxis in Sports Injury. , 2011, , 127-134.		0
1178	Novel therapies for treating atrial fibrillation. World Journal of Cardiovascular Diseases, 2012, 02, 242-259.	0.0	0
1181	Pediatric Venous Thromboembolism. , 2012, , 3145-3158.		0
1183	New anticoagulant drugs. Medicinski Casopis, 2012, 46, 145-154.	0.1	0
1188	Total kalÃ§a artroplastisinde venÃ¶z tromboemboli profilaksisi. TÃ¼rk Ortopedi Ve Travmatoloji BirliÄŸi DerneÄŸi, 2013, 12, 276-280.	0.0	0

#	ARTICLE	IF	CITATIONS
1227	A Clinically Oriented Review of the Landmark Clinical Trials Comparing Warfarin and Aspirin to Novel Oral Anticoagulants in Atrial Fibrillation. , 2019, 1, 1-5.		0
1228	Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation. Journal of Stroke, 2019, 21, 259-275.	1.4	6
1229	Reversal of Oral Anticoagulants in the Elderly. , 2020, , 67-75.		0
1230	Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience. World Journal of Hepatology, 2020, 12, 197-209.	0.8	0
1231	Profilaxia do tromboembolismo venoso nas cirurgias do tornozelo e do pÃ©. Revista Brasileira De Ortopedia, 2021, 56, 697-704.	0.2	1
1232	Venous Thromboembolism and Orthopedic Surgery. , 2020, , 295-305.		0
1233	Comparing Prophylactic Effect of Rivaroxaban and Enoxaparin on Thromboembolism After Total Hip or Knee Arthroplasty. Journal of Research in Orthopedic Science, 2020, 7, 13-22.	0.1	1
1234	Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor. P and T, 2009, 34, 238-44.	1.0	10
1235	New options in anticoagulation for the prevention of venous thromboembolism and stroke. P and T, 2011, 36, 86-99.	1.0	5
1236	Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P and T, 2011, 36, 518-28.	1.0	1
1237	Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. CADTH Technology Overviews, 2010, 1, e0111.	0.5	1
1238	Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto). P and T, 2013, 38, 45-50.	1.0	1
1239	Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. American Health and Drug Benefits, 2012, 5, 115-22.	0.5	3
1240	Thromboprophylaxis and orthopaedic surgery: options and current guidelines. The Malaysian Journal of Medical Sciences, 2014, 21, 71-7.	0.3	6
1241	Pharmacological prevention of venous thromboembolism in orthopaedic surgery. Clinical Cases in Mineral and Bone Metabolism, 2014, 11, 192-5.	1.0	7
1242	A Pilot Study Comparing Hospital Readmission Rates In Patients Receiving Rivaroxaban or Enoxaparin After Orthopedic Surgery. P and T, 2016, 41, 376-80.	1.0	1
1243	How we treat bleeding associated with direct oral anticoagulants. Blood Transfusion, 2016, 14, 465-73.	0.3	8
1244	The ultimate anticoagulants?. Cardiovascular Journal of Africa, 2010, 21, 55-6.	0.2	0

#	ARTICLE	IF	CITATIONS
1245	Use of direct oral anticoagulants in daily practice. American Journal of Blood Research, 2018, 8, 57-72.	0.6	18
1246	Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery. Blood Transfusion, 2019, 17, 157-162.	0.3	4
1248	The effect of a new oral anticoagulant (Rivaroxaban) on implants pull-out strength. An experimental study in rats. Journal of Frailty, Sarcopenia and Falls, 2017, 2, 1-5.	0.4	0
1249	Anticoagulation-related nephropathy for the internist: a concise review. American Journal of Cardiovascular Disease, 2020, 10, 301-305.	0.5	0
1250	Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery. Cureus, 2021, 13, e19691.	0.2	3
1251	Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematology Reports, 2021, 13, 9239.	0.3	2
1252	Prevention of Venous Thromboembolic Events in Patients with Lower Leg Immobilization after Trauma: Systematic Review and Network Meta-Analysis with Meta-Epidemiological Approach. SSRN Electronic Journal, 0, , .	0.4	0
1253	Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. The Cochrane Library, 2022, 2022, CD005258.	1.5	19
1254	Efficacy and Safety of Enoxaparin versus New Oral Anticoagulants to Prevent Venous Thromboembolism after Total Hip Replacement: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2022, 12, 107.	1.1	4
1255	New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 775126.	1.6	6
1256	Aspirin thromboprophylaxis in joint replacement surgery. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12649.	1.0	1
1257	The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis. Journal of Orthopaedics, 2022, 30, 1-6.	0.6	2
1258	Preventing Venous Thromboembolism after elective total hip arthroplasty surgery – are the current guidelines appropriate? Venous thromboembolism prophylaxis in elective total hip arthroplasty surgery. Journal of Clinical Orthopaedics and Trauma, 2022, 26, 101782.	0.6	0
1259	Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa – PAR2-Mediated Autophagy Suppression. JACC Basic To Translational Science, 2021, 6, 964-980.	1.9	17
1261	Recommendations from the ICM-VTE: Hip & Knee. Journal of Bone and Joint Surgery - Series A, 2022, 104, 180-231.	1.4	28
1262	The Impact of Direct Oral Anticoagulant Prophylaxis for Thromboembolism in Thrombophilic Patients Undergoing Abdominoplastic Surgery. Healthcare (Switzerland), 2022, 10, 476.	1.0	2
1263	Editor's Choice – Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. European Journal of Vascular and Endovascular Surgery, 2022, 63, 465-474.	0.8	4
1264	Recommendations from the ICM-VTE: General. Journal of Bone and Joint Surgery - Series A, 2022, 104, 4-162.	1.4	14

#	ARTICLE	IF	CITATIONS
1265	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.	0.8	11
1266	Treatment and outcomes of anticoagulated geriatric trauma patients with traumatic intracranial hemorrhage after falls. <i>European Journal of Trauma and Emergency Surgery</i> , 2022, 48, 4297-4304.	0.8	4
1267	Global Research Status and Trends in Venous Thromboembolism After Hip or Knee Arthroplasty From 1990 to 2021: A Bibliometric Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 837163.	1.2	3
1268	Effects of <i>MaiLiuPian</i> on carotid thrombosis in rats and acute pulmonary embolism in mice and its antithrombotic mechanism. <i>Journal of Food Biochemistry</i> , 2022, 46, e14143.	1.2	1
1269	Is there consensus on the perioperative management of Xa inhibitors in patients undergoing elective spine surgery? A survey of current spine surgeon practices. <i>Journal of Spine Surgery</i> , 2021, 7, 458-466.	0.6	0
1272	Changes in Thromboelastography to Predict Ecchymosis After Knee Arthroplasty: A Promising Guide for the Use of Anticoagulants. <i>Frontiers in Surgery</i> , 2022, 9, 871776.	0.6	1
1273	Short-Term Postoperative Use of Rivaroxaban to Prevent Radial Artery Occlusion After Transradial Coronary Procedure: The RESTORE Randomized Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011555.	1.4	11
1274	A new era of anticoagulation. <i>Acta Clinica Belgica</i> , 2012, 67, 394-8.	0.5	0
1276	Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. <i>European Cardiology Review</i> , 0, 17, .	0.7	3
1277	Thai Consensus on Venous Thromboembolism in Hip and Knee Surgery. , 2017, 1, 29-43.		0
1278	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
1281	Rivaroxaban After Transcatheter Aortic Valve Replacement: A Critical Appraisal of the GALILEO Trial. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0
1282	Direct oral anticoagulants and peripheral arterial disease. , 2022, 1, 76-79.		0
1283	A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma. <i>Journal of Orthopaedic Trauma</i> , 2022, 36, 615-622.	0.7	1
1284	Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epidemiological approach. <i>PLoS Medicine</i> , 2022, 19, e1004059.	3.9	4
1285	Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4070.	1.0	1
1286	Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. , 2023, , 407-416.		0
1287	2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. <i>European Heart Journal</i> , 2022, 43, 3826-3924.	1.0	298

#	ARTICLE	IF	CITATIONS
1288	Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 502-523.	1.0	1
1289	Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis. <i>Vascular Medicine</i> , 0, , 1358863X2211152.	0.8	0
1290	Prevention of thromboembolism in orthopedic surgery: Application of rivaroxaban in arthroplastic procedures. , 2022, 1, 70-75.		0
1291	Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation “ in-group comparison. , 2022, 20, 26-31.		0
1292	Thromboprophylaxis Following Hip and Knee Surgery. <i>Canadian Journal of General Internal Medicine</i> , 2022, 17, 33-40.	0.6	0
1293	Risk factors for venous thromboembolism following fractures isolated to the foot and ankle fracture. <i>PLoS ONE</i> , 2022, 17, e0276548.	1.1	5
1294	Kidney Dysfunction After Traumatic Brain Injury: Pathophysiology and General Management. <i>Neurocritical Care</i> , 2023, 38, 504-516.	1.2	6
1295	Patient Blood Management in Vascular Surgery. <i>Anesthesiology Clinics</i> , 2022, 40, 605-625.	0.6	1
1297	The Indications of Temporary Inferior Vena Cava Filter for Deep Vein Thrombosis and Pulmonary Embolism. <i>The Japanese Journal of Phlebology</i> , 2011, 22, 17-24.	0.0	1
1298	Consensus Recommendations for Preventing and Managing Bleeding Complications Associated with Novel Oral Anticoagulants in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 593-602. .	0.2	3
1299	Minimisation of Bleeding Risks Due to Direct Oral Anticoagulants. <i>European Medical Journal Hematology</i> , 0, , 78-90.	0.0	0
1300	Thromboprophylaxis in gynaecology: a review of current evidence. <i>The Obstetrician and Gynaecologist</i> , 2023, 25, 59-71.	0.2	1
1301	Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 63, .	0.6	6
1302	Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .	0.4	2
1303	Oral Surgery in Patients Taking Direct Oral Anticoagulants (DOACs): A Practical Review of the Literature. <i>The Journal of Dentists</i> , 0, 7, 8-16.	0.1	0
1304	Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial. <i>Renal Failure</i> , 2023, 45, .	0.8	0
1305	Clinical Studies with Anticoagulants that Have Changed Clinical Practice. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 242-254.	1.5	4
1306	Efficacy of 11 anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e32635.	0.4	0

#	ARTICLE	IF	CITATIONS
1307	Novel therapeutic medications for venous thromboembolism prevention in trauma patients: Findings from the Consensus Conference to Implement Optimal Venous Thromboembolism Prophylaxis in Trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2023, 94, 479-483.	1.1	6
1308	Trends in Venous Thromboembolism After Shoulder Arthroplasty in the United States: Analysis Following the 2009 American Academy of Orthopaedic Surgeons Clinical Practical Guidelines. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2023, 31, 364-372.	1.1	3
1309	Trends of Venous Thromboembolism After Total Hip Arthroplasty in the United States: Analysis From 2011 to 2019. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2023, 31, e376-e384.	1.1	6
1311	Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. , 2013, , 275-282.		0
1312	Rivaroxaban frente a heparinas de bajo peso molecular para la prevención de la tromboembolia venosa posterior al reemplazo total de cadera o rodilla: revisión sistemática de la literatura y metanálisis. <i>latreia</i> , 2013, 26, .	0.1	0
1313	Approaches for optimizing venous thromboembolism prevention in injured patients: Findings from the consensus conference to implement optimal venous thromboembolism prophylaxis in trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2023, 94, 469-478.	1.1	14
1314	Downregulation of miR-125a-5p Promotes Endothelial Progenitor Cell Migration and Angiogenesis and Alleviates Deep Vein Thrombosis in Mice Via Upregulation of MCL-1. <i>Molecular Biotechnology</i> , 2023, 65, 1664-1678.	1.3	2
1315	Prolonged thromboprophylaxis with rivaroxaban after bariatric interventions: single centre experience. <i>Polski Przegląd Chirurgiczny</i> , 2023, 95, 1-5.	0.2	1
1316	Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. <i>Journal of Arthroplasty</i> , 2023, , .	1.5	0
1317	Statistical Fragility of Venous Thromboembolism Prophylaxis Following Total Joint Arthroplasty. <i>Arthroplasty Today</i> , 2023, 20, 101111.	0.8	0
1318	COMPARATIVE STUDY OF RIVAROXABAN WITH ENOXAPARIN AS THROMBO PROPHYLAXIS IN TOTAL HIP REPLACEMENT. , 2023, 20, .		0
1319	DVT Prophylaxis with Heparin and Heparin-Like Drugs (UH, LMWH, Fondaparinux, and Rivaroxaban) Used in Combination with Neuraxial Anesthesia and Deep Plexus Blocks. , 2013, , 385-403.		0
1327	Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 247-255.	1.0	0
1343	DOACs for the Medical Management of Venous Thromboembolism in Adults. , 0, , .		0